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ABSTRACT 
Introduction: 
Tuberculosis (TB) remains a contributor to the burden of disease in the world especially in 
resource limited Africa yet adherence to anti-tuberculosis (anti-TB) treatment remains a 
challenge.  
Objectives: To address this challenge, our study was to ascertain the extent of poor adherence to 
anti-TB treatment, to describe the demographic factors of patients on anti-TB treatment, to 
investigate the factors associated with poor adherence to anti-TB treatment in Tororo district, and 
to make respective recommendations to improve adherence to anti-TB treatment in order to 
contribute to the reduction of the TB burden in the world. 
Study design and Methodology: In this cross sectional study, we utilized data from 200 patients 
on anti-TB treatment from Tororo district Uganda. Participant’s socio-demographic, medical, 
anti-TB treatment, and economic data were collected. Determinants of poor adherence to anti-TB 
treatment were investigated using interactive expansion logistic regression by means of Stata, 
version 10.1. 
Results: More males (60%) had TB compared to females. Most participants (71%) were ≤ 45 
years, and a considerable proportion of participants (21%) had no education. Most participants 
(90%) lived alone. Nearly two thirds of the participants (65%) were adherent to their anti-TB 
treatment. Using a p-value of < 0.05, a  previous diagnosis of TB (adjusted odds ratio [AOR] 3.9; 
p-value 0.045), perceived pill burden causing quitting of anti-TB treatment (AOR 6.5; p-value 
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0.010), only agreeing that missing doses or taking them incorrectly can ruin anti-TB treatment 
(AOR 2.6; p-value 0.013), being on adult anti-TB re-treatment regimen (AOR 3.4; p-value of 
0.049), and surprisingly having electricity in the house hold (AOR 2.22; p-value 0.045) were all 
independently associated with poor adherence to anti-TB treatment.  
Recommendations: TB patients (especially retreatment patients) should receive counselling to 
swallow all their medication, fixed dose combinations and DOTS should be encouraged in the 
management of patients, and research to condense all the various drugs in one pill should be 
encouraged. We also warranty further research to test and confirm the association between 
household electricity and poor anti-TB treatment adherence. 
 (331 words) 
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CHAPTER ONE: INTRODUCTION/BACKGROUND TO THE PROBLEM 
The Millennium Development Goal (MDG) of halting and reversing the Tuberculosis (TB) 
epidemic by 2015 has been achieved. However, the global burden of TB remains enormous. 
Tuberculosis has claimed an estimated 1.4 million lives, 29% having been Human 
Immunodeficiency Virus (HIV) infected (WHO, 2016). There were 10.4 million new cases with 
56% being males, 34% being females, 10% being children, and 11% being people living with 
HIV (PLHA) in the year 2015 alone (WHO, 2016).  
The End TB strategy goal is to end the global TB epidemic and some of its targets are to reduce 
the number of TB deaths and TB incidence by 95% and 90% respectively, and to attain a TB 
treatment success of 90% by the year 2035 (WHO, 2014c). 
The Global Plan to Stop TB partnership made a commitment to eliminate TB as a public health 
problem by 2050 and achieve a global incidence of active TB of less than one case per one 
million population per year. To achieve this, reinforcing adherence to anti-TB treatment is one of 
the essential parameters that will decrease the source of TB and at the same time prevent 
development of drug-resistant TB. One of the components of the Global Plan to Stop TB is the 
research and development element to develop new tools essential to transform the control of TB, 
as a basis for its elimination (WHO, 2010b).  
In 2015 in Uganda, the TB incidence risk was 202 per 100,000 population including those with 
HIV associated TB. The incidence risk of multi-drug resistant TB (MDR-TB) in 2015 was 12 per 
100,000 for (WHO, 2016). A review of TB treatment default studies in Sub-Saharan African 
countries including Uganda, Zambia, and Ethiopia by Castelnuovo (2014) revealed that the 
http://etd.uwc.ac.za/
 12 
 
proportion of TB patients that defaulted anti-TB treatment ranged from 11% to 30%. This 
contributed to lack of attainment of a treatment success rate of 100% (Castelnuovo, 2010). 
Various measures to decrease TB infection such as community referral for TB treatment and TB 
treatment adherence support in basic management units have been provided in various countries 
(WHO, 2014b). 
Uganda’s treatment success rate had neither reached nor exceeded 85%, though there had been 
an improvement from a rate of 73% in 2011 to 77% in 2012, remaining below the global 
treatment success target (WHO, 2014b). However, currently, Uganda is not listed among the 
high TB burden countries (WHO, 2016).  
Prevention and control of TB is one of the priority services of the Ugandan health sector. Uganda 
adopted a decentralized model of TB control called Community-based DOTs (CB-DOTs) as a 
national policy (MOH, 2008). The Uganda national TB control programme adopted the Stop TB 
and DOTS strategy of detecting 70% of new TB infectious cases, and to successfully treat 85% 
of them using the DOTs strategy. This has not been achieved due to two key contributors: 
inadequate health promotion due to lack of strategic communication guidelines; and an 
environment of HIV/AIDS complicating the management of TB (MOH, 2008). In addition, 
though the government adopted CB DOTS, there is shortage of medical personnel in many 
health facilities. Medical personnel have to monitor CB-DOTs implementation in their health 
facilities’ community catchment areas. 
Furthermore, part of the six core functions the WHO pursues in addressing TB is developing 
evidence based policies, strategies and standards for TB prevention, care and control (WHO, 
2014c). To achieve part of these core functions, re-enforcing and improving adherence to anti-
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TB treatment are important. In TB care, health practitioners must not only prescribe an 
appropriate anti-TB regimen but must also assess and address poor patient adherence when it 
occurs so that they (the practitioners) can be able to ensure adherence to the regimen until 
treatment is completed in order to achieve a desirable treatment outcome (Tuberculosis Coalition 
for Technical Assistance (TBCTA), 2006). Poor adherence to TB therapy has been found to be 
one of the major obstacles in the global fight against TB, and there is a need to identify treatment 
adherence interventions and to test various adherence interventions (WHO, 2010b). 
In Uganda, poor adherence to anti TB treatment was revealed to be one of the significant 
predictors of treatment failure in a retrospective unmatched case control study with an odds ratio 
(OR) of 14.59 (95% CI 3.04-70.15) in a hospital setting (Namukwaya, Nakwagala, Mulekya, 
Mayanja-Kizza, & Mugerwa, 2011). Provision of anti-TB drugs in the management of TB in 
resource limited settings is a very important aspect of TB control. However, the long-term 
success of anti TB treatment in resource limited settings requires establishing the levels of poor 
adherence and factors that determine poor adherence to anti TB treatment. 
PROBLEM STATEMENT 
In order to eliminate TB from the world, effective preventive measures as well as optimal case 
management is required (WHO, 2008). In order to control TB, the magnitude and core causes of 
poor treatment outcomes such as poor adherence to treatment need to be known. In Uganda, the 
treatment success rate of newly diagnosed and relapse TB cases as of 2012 was 77%, remaining 
less than the set global target of 85% (WHO, 2014b). The causes of this poor treatment outcome 
have not been adequately investigated or completely addressed.  
http://etd.uwc.ac.za/
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Poor adherence to anti-TB treatment can lead to treatment failure, MDR-TB, or death (WHO, 
2010a). Good adherence is essential for maximum clinical benefit from anti-TB treatment. The 
level of adherence to anti-TB treatment has not been measured in Tororo district. It is from this 
insight that we did conduct the study to ascertain the anti-TB treatment poor adherence rate, and 
the factors associated with poor adherence to anti-TB treatment. 
AIMS AND OBJECTIVES 
Aim 
The aim of the study was to describe adherence levels and explore the factors influencing 
adherence among persons on anti-TB treatment in Tororo district. 
Objectives 
 To describe the socio-demographic profiles of persons on anti TB Treatment for at least 2 
months in Tororo district. 
 To determine the extent of poor adherence to anti-TB treatment among persons on anti TB 
Treatment for at least 2 months in Tororo district. 
 To identify factors that influence TB treatment adherence among persons on anti TB 
Treatment for at least 2 months in Tororo district. 
SIGNIFICANCE OF THE STUDY 
The study will provide insight into the level of adherence, and patients and health services 
factors that result in poor adherence to anti-TB treatment thus contribute to the existing body of 
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knowledge.  The findings of the study will contribute to establishing, revising, or amending 
strategies and guidelines to improve adherence to anti-TB treatment by addressing the mitigating 
factors that will be found to be causing poor adherence anti-TB treatment in order to achieve 
better outcomes of anti-TB treatment. 
DEFINITION OF KEY TERMS 
The following are definitions of the key concepts used in this study. Please find the full 
conceptual and operational study definitions in Appendix 1. 
Adherence 
“Adherence to long-term therapy is defined as the extent to which an individual’s behavior 
corresponds to a health care provider’s agreed upon recommendations” (WHO, 2003:3).   
Antiretroviral therapy 
Anti-retroviral therapy involves using drug combinations to treat HIV infection where three or 
more different classes of antiretroviral drugs are used to stop the HIV multiplication by acting 
through different stages of the HIV life cycle (WHO, 2006:24). 
Compliance 
Compliance is the continuous, correct and uninterrupted taking of prescribed medication as 
directed by the healthcare professional (Aït-Khaled N, Alarcón E, Armengol R, Bissell K, 
Boillot F, Caminero J A, Chiang C-Y, Clevenbergh P, Dlodlo R, Enarson D A, Enarson P, 
Fujiwara P I, Harries A D, Heldal E, Hinderaker S G, Lienhardt C, Monedero I, Rieder H L, 
Rusen I D, Trébucq A, Van Deun , 2010:12). 
http://etd.uwc.ac.za/
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DOTS 
Directly observed treatment, short-course (DOTS) is an international strategy used in the 
implementation of the basics of TB case-finding and cure. It includes, political commitment, 
case-detection through quality bacteriology, short-course chemotherapy, adequate drug supply, 
and comprehensive recording and reporting systems (WHO, 2006b). 
First-line TB drugs 
First-line TB drugs are the drugs used in the treatment of susceptible TB (WHO, 2010:30) and 
for this study they are rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin. 
Incidence 
Incidence is a measure of the probability of occurrence of a given condition in a population 
within a specified period of time. Incidence proportion (cumulative incidence) is the number of 
new cases with a particular condition (which is TB in our study) in a specified period of time per 
population initially at risk (Rothman, Lash, & Greenland, 2008).  
Multidrug-resistant tuberculosis (MDR-TB) 
This is tuberculosis caused by organisms that do not respond to or show resistance to at least 
rifampicin and isoniazid (WHO, 2014a, 2016). 
Prevalence 
Prevalence is the number of cases with a particular condition per 10,000 or 100,000 population. 
In this study we used period prevalence which is the number of cases per 100,000 people that 
had Tuberculosis during a one year period, and includes people who already had the condition at 
http://etd.uwc.ac.za/
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the start of the study period as well as those who acquired it during that period (Rothman, 
2012:53).   
Rural Uganda 
In this study rural Uganda refers to the remote parts of Uganda accessed only through marram 
roads where most of the local people are peasants who depend on subsistence farming with 
limited or no access to hydroelectric power, and limited clean water and health facilities. 
Tuberculosis (TB) 
Tuberculosis is a chronic infectious disease caused by an organism called Mycobacterium 
tuberculosis or Mycobacteria bovis, transmitted through droplet infection when the infected 
person sneezes or coughs, or through drinking of unpasteurized milk from an infected animal; 
presenting with clinical features such as cough, chest pain, sputum production, weight loss, 
fevers and night sweats (Aït-Khaled N, Alarcón E, Armengol R, Bissell K, Boillot F, Caminero J 
A, Chiang C-Y, Clevenbergh P, Dlodlo R, Enarson D A, Enarson P, Fujiwara P I, Harries A D, 
Heldal E, Hinderaker S G, Lienhardt C, Monedero I, Rieder H L, Rusen I D, Trébucq A, Van 
Deun , 2010:5; MOH, 2012:90-91).  In Tororo, TB is a chronic infection caused by bacteria with 
clinical features that include but not limited to chronic cough of two weeks or more, fevers with 
excessive night sweats, weight loss, and lymph nodes enlargement. A TB diagnosis is confirmed 
by two sputum ZN stain for alcohol acid fast bacilli (AAFB) or polymerase chain reaction (PCR) 
Gene xpert test for HIV positive patients (MOH, 2012). 
SUMMARY OF THE RESEARCH STUDY 
 In summary of this research study, the rest of the thesis is outlined as follows: 
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 Chapter 2: Literature Review. Chapter 2 shows a thorough review of the literature 
related to anti-TB treatment adherence to furnish the researcher on all accessible 
information or knowledge that is already published and discussed on adherence to anti-
TB treatment.  
 Chapter 3: Design and Methodology. This chapter shows the study design and 
methodology used to address the research question. It talks about our study design, study 
settings, study population, sampling, data collection, data collection instrument, data 
analysis validity and reliability, generalizability, ethical considerations, and scope and 
limitations of the study. 
 Chapter 4: Results. Here we have the presentation of our study findings. The results 
chapter presents the results from the analysis of the factors associated with poor 
adherence to anti-TB treatment among Patients on anti-TB treatment in Tororo district. 
Our analysis results include a description of the demographic characteristics of our study 
participants, followed by univariate and multivariate analysis. 
 Chapter 5: Discussion. In the discussion, our study findings are related to literature.  
 Chapter 6: Conclusions and recommendations. Conclusions and recommendations 
emanating from our study findings are described.  
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CHAPTER TWO: LITERATURE REVIEW 
INTRODUCTION  
This literature review focuses on describing adherence levels and exploring the factors 
influencing adherence among persons on anti-TB treatment. The chapter starts with an overview 
of the TB and HIV associated TB co-infection status and anti-TB treatment adherence status in 
Uganda. This is followed by factors affecting adherence to anti-TB treatment.   
TB AND TB/HIV CO-INFECTION STATUS AND ANTI-TB TREATMENT 
ADHERENCE STATUS IN UGANDA 
According to the 2016 WHO Uganda tuberculosis profile, the mortality of TB in Uganda is 
12/100,000 population (excluding HIV+TB) and 17/100,000 population (HIV+TB only). The TB 
prevalence was found to be 159/100,000 population (including HIV+TB) with an incidence of 
161/100,000 population (including HIV+TB) and 73/100,000 population (for HIV+TB only) 
(WHO, 2016). The proportion of TB with MDR TB was 1.4% for new and 12% for retreatment 
cases (WHO, 2016). A high proportion of TB patients (100%) know their HIV status and almost 
half (42%) of these patients are living with HIV and AIDS (WHO, 2016). A review of TB 
treatment default studies in Sub-Saharan African countries including Uganda, Zambia, and 
Ethiopia by Castelnuovo (2014), revealed the proportion of patients defaulting Tuberculosis to 
vary from 11.3% to 29.6% (Castelnuovo, 2010).  
The Directly observed therapy shortcourse (DOTS) strategy is the basic package that underpins 
the Stop TB Strategy and has five components that include government commitment, case 
detection by sputum smear microscopy, directly observed standardized treatment regimen, a 
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regular drug supply, and standardized recording and reporting. DOTS is the internationally 
recommended approach behind the goal of eliminating TB as a public health problem and, 
ultimately to securing a world free of TB (WHO, 2009). However, we cannot secure a world free 
of TB if the control measures and specifically in this case, adherence which determines treatment 
outcome are not addressed.  
ANTI-TB TREATMENT 
The standardized anti-TB treatment regimens recommended by WHO include five essential 
medicines designated as “first line”: isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol 
(E) and streptomycin (S). For treatment purposes, patients are categorized as previously 
untreated and previously treated. All new pulmonary TB patients receive a regimen containing 6 
months of rifampicin (2HRZE/4HR or /4HRE where there are high levels of H resistance), with 
daily dosing or thrice weekly dosing if DOTs; and 2HRZES/1HRZE/5HRE for previously 
treated patients (WHO, 2002, 2010d). 
WHO recommends the use of fixed-dose combinations (FDCs) of drugs for the treatment of all 
TB patients. Several advantages of FDC s over individual medicines (or single-drug 
formulations) have been identified and these include a high likelihood of prescription errors 
being less frequent, and patients having to swallow fewer tablets which may encourage 
adherence to treatment (WHO, 2002) 
In Uganda, adherence to TB treatment is when a patient takes his/her drugs according to the 
prescription instructions, following the dosage, number of times, and number of days without 
missing any sessions until all the medication is completely taken (MOH, 2008). Adherence to TB 
treatment has been revealed to be the strongest determinant of tuberculosis treatment outcome 
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(Namukwaya et al., 2011; Rocha, Pereira, Ferreira, & Barros, 2003; WHO, 2010a) and it has 
also been revealed that poor adherence to TB treatment or suboptimal treatment can result into 
treatment failure, MDR TB, or death if not addressed (WHO, 2010a).  
FACTORS AFFECTING ADHERENCE TO ANTI-TB TREATMENT 
As per the Uganda Clinical Guidelines (2010), short course TB treatment regimens are 
dependent on patient treatment status (first time treatment or re-treatment) and are carried out in 
phases (initial and continuation phases). Each regimen starts with an initial (intensive) phase of 
2-3 months and continuation Phase of 4-6 months depending on the drug combinations used.  
According to the Uganda TB treatment guidelines (MOH, 2010:45-46),  
“one of the most important risk factors for development of drug-resistant Tuberculosis is 
inadequate anti-TB treatment because it leads to mutation in drug-susceptible bacilli 
making them drug resistant, and factors instigating inadequate anti-TB treatment include 
poor adherence which can also be secondary to many other factors.” 
There are various factors that can determine adherence to TB treatment and consequently TB 
treatment outcome. These factors include age, sex, education, TB knowledge, treatment support, 
supervision of drug taking, alcohol and tobacco use, improvement in treatment, economic 
support, financial status, cost of treatment, distance from health facility, travel related costs, co-
morbid health condition, and partner status. Each of these factors will be discussed in turn below.   
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Age and sex 
Increasing age and male sex may be associated with poor adherence to treatment. A study 
conducted in Europe revealed increasing age to be associated with poor treatment success among 
patients on anti-TB treatment (Falzon, Strat, Belghiti, & Infuso, 2005). This is in line with 
another study in Nigeria that also revealed younger age groups to be associated higher adherence 
to anti-TB treatment (Anyaike, Musa, Babatunde, Bolarinwa, Durowade & Ajayi, 2013). 
Likewise, male sex was found to be associated with poor adherence to anti-TB medication in a 
cross-sectional study conducted in Thailand (Peltzer & Pengpid, 2015). 
Patient’s education 
Patients’ education may be associated with good treatment adherence. A cross sectional survey 
in Nigeria revealed that a high proportion of respondents with no education (19.4%) missed their 
anti-TB treatment drugs (Anyaike et al., 2013). This concurs with a study in 2012 by Finlay et al 
who also found cases of poor adherence to anti-TB treatment to be more likely to lack education 
as compared to controls in a retrospective case control study in South Africa (Finlay et al., 
2012). In line with this, illiteracy was also found to be associated with poor compliance to 
directly observed therapy (Gopi, Vasantha, Muniyandi, Chandrasekaran & Balasubramanian, 
2007). 
Patient TB knowledge and consultation of traditional healers 
Inadequate patient TB knowledge and consultation of traditional healers may be associated with 
poor adherence to anti-TB treatment. The patient’s knowledge about TB in terms of treatment, 
treatment duration, medication side effects and counselling was found to be predictive of 
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patients’ adherence to TB treatment (Clark, Karagoz, Apikoglu-Rabus, & Izzettin, 2007; Tekle, 
Mariam, & Ali, 2002; Zhou et al., 2012). On the other hand, a case control study in South Africa 
revealed seeing a traditional healer during anti-TB treatment to be associated with anti-TB 
treatment default (Finlay Lancaster, Holtz, Weyer, Miranda & van der Walt., 2012). 
Treatment support 
Treatment support is a likely determinant of good adherence to treatment. Support from 
treatment supporters and/or family members were found to be crucial factors in determining 
adherence to TB treatment and treatment success (Tekle et al., 2002). This is also in line with a 
study conducted in Shandong China by Zhou et al (2012) that revealed divorce or spouse 
bereavement to be risk factors for non-adherence (Zhou et al., 2012).  
Forgetfulness and stigma 
Forgetfulness and stigma may be likely causes of poor adherence. An institution based cross 
sectional survey conducted in north Ethiopia revealed forgetfulness to be a main cause of high 
rates of non-adherence to anti-TB treatment with adjusted OR of 7.04 (Adane, Alene, Koye, & 
Zeleke, 2013).  
Stigma was found to influence patient’s decisions on TB treatment adherence in a cross sectional 
study in South Africa (Cramm, Finkenflügel, Møller, & Nieboer, 2010). 
Drug supply and supervision of drug taking 
Inadequate drug supply and non-supervised drug taking may be associated with poor adherence. 
Shortage of adequate anti TB drug supply was found to be associated with poor adherence to 
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anti-TB treatment in a cross-sectional study in India (Bagchi, Ambe, & Sathiakumar, 2010). 
However, though self-supervision by patients was found to have more TB treatment success as 
compared to directly observed therapy by  6% with a 90% CI of -5.1 – 17.0 in a randomized 
controlled trial in South Africa (Zwarenstein, Schoeman, Vundule, Lombard, & Tatley, 1998), 
this was contrary to a study in China which revealed self-supervision to be a risk factor for non-
adherence in migrant workers in 12 counties of Shandong (Zhou et al., 2012) and also contrary 
to another study which also revealed that in remote/poor areas of China, direct observation of TB 
treatment by health care staff was associated with better adherence to drug therapy (Yao et al., 
2011).  
Alcohol and Tobacco use 
Alcohol and Tobacco use may be associated with poor adherence. TB patients who abuse alcohol 
were at 4.4 times increased risk of defaulting ATT  in an urban primary care clinics in Kampala 
(Adjusted odds ratio (AOR) of 4.4, (95% CI 1.8–13.5) (Sendagire, Schim Van der Loeff, 
Kambugu, Konde-Lule, & Cobelens, 2012). Likewise, tobacco use was found to be associated 
with TB treatment non-adherence in a cross-sectional study in South Africa (Naidoo et al., 
2013). 
Improvement on treatment 
Improvement on anti-TB treatment may be associated with poor adherence. Feeling better was 
found to be a determinant of failure to comply with TB treatment among TB patients in a cross 
sectional study in Zambia (Kaona, Tuba, Siziya, & Sikaona, 2004). This was conducted as a 
household-based survey in six randomly selected catchment areas of Ndola Zambia. 
Furthermore, previous non-compliance (a non-modifiable factor) was found to be associated with 
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non-compliance to anti-tuberculosis treatment in an unmatched case–control study in patients 
diagnosed with tuberculosis in four Peruvian provinces (Culqui et al., 2012). 
Economic support, financial status, and cost of treatment 
Economic support low treatment cost and a good financial status may facilitate adherence. This 
is shown by a qualitative study conducted in Addis-Ababa which revealed that food provision 
and minimal financial support may facilitate adherence to TB treatment (Gebremariam, Bjune, & 
Frich, 2011). This is also in line with a qualitative research review in China which revealed cost 
of treatment to be the most cited reason for TB treatment default (Long, Smith, Zhang, Tang, & 
Garner, 2011) and also in line with Zhou et al (2012) who revealed weak incentives for treatment 
adherence to be a risk factor for non-adherence in migrant TB patients in Shandong. 
Furthermore, poverty was also found to be a significant predictor of TB treatment non-adherence 
in South Africa (Naidoo et al., 2013).  
Distance from health facility and travel related costs 
Distance from the health facility and travel related costs may be associated with poor adherence. 
A Sub-Saharan African articles review by Castelnuovo (2010), revealed distance from the 
hospital to be a risk factor for defaulting treatment (Castelnuovo, 2010). Also, difficulty in 
accessing a health facility, change of treatment facility, and change of residence were associated 
with poor adherence to TB treatment (Gopi et al., 2007; Nuwaha, 1999; Sendagire et al., 2012). 
Travel-related costs were also significantly associated with non-adherence in newly-diagnosed 
patients in a cross-sectional study in Mumbai, India (Bagchi et al., 2010). Also, long waiting 
times for TB related services such as review by a health professional was found to have a 
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negative impact on patient TB treatment adherence in a study in Ethiopia (Nezenega, Gacho, & 
Tafere, 2013).  
Previous anti-TB treatment history 
Previous anti-TB treatment history may be associated with poor adherence. A retrospective case 
control study in South Africa revealed a history of TB treatment default to be associated with 
anti-TB treatment default with an adjusted odds ratio of 6 (Finlay et al., 2012). 
Presence of a co-morbid health condition and partner status 
A co-morbid health condition and partner status may cause poor adherence. According to the 
WHO Country TB profile for Uganda, 42% of the HIV associated TB (HIV/TB) co-infected 
patients with known HIV status are positive for HIV and 88% of these are on anti-retroviral 
therapy (WHO, 2016). HIV infection was found to be a determinant of TB treatment non-
adherence in patients treated as outpatients (Rocha et al., 2003). This is in line with a study by 
Kliiman and Altraja (2009) who revealed HIV infection to be a risk factor for poor treatment 
outcome in MDR-TB patients (Kliiman & Altraja, 2009). Having one or more co-morbid health 
conditions and having an HIV positive partner were also found to be associated with poor 
compliance to TB treatment in a cross-sectional study in South Africa (Naidoo et al., 2013).  
CONCLUSION 
In this chapter we reviewed literature in which we looked at TB and TB/HIV co-infection status 
in Uganda, anti-TB treatment adherence status in Uganda, and standardized anti- TB treatment 
regimens. We also looked at factors affecting adherence to anti-TB treatment which include age, 
sex, patient’s education, patient TB knowledge, consultation of traditional healers, treatment 
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supporters, supervision of drug taking, alcohol and tobacco use, improvement on treatment, 
economic support, financial status, cost of treatment, distance from health facility, travel related 
costs, previous anti-TB treatment history, presence of a co-morbid health condition, & partner 
status. 
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CHAPTER THREE: STUDY DESIGN AND METHODOLOGY 
In this chapter we describe the study design, study settings, study population, sampling, data 
collection, data collection instrument, data analysis validity and reliability, generalizability, 
ethical considerations, and conclude with the scope and limitations of the study.  
STUDY DESIGN AND SETTING  
A cross-sectional study design was conducted to determine the prevalence of poor adherence in 
people on anti TB treatment and the factors related to poor adherence among people on anti-TB 
treatment within Tororo district.  
Study Setting / Location 
This study was conducted in Tororo district. Tororo district is an administrative district located 
in the Eastern Central region of Uganda, bordering Kenya. The 2015 population estimate of 
Tororo is 538,000, 50.8% being female by gender. There are two main tribes; the Jopadhola, and 
the Itesots, and agriculture is the main source of income (UBOS, 2014:110). The providers of TB 
and/or TB/HIV care and treatment in Tororo include Tororo district government hospital, The 
Aids Support Organization (a non-governmental organisation), St Anthony’s hospital (a private 
hospital), Mukujju Health Centre, and Nagongera Health Centre. Our study participants were 
recruited from the three facilities providing anti-TB treatment under government sponsorship. 
The facilities include Mukujju Health Center, Nagongera Health Center and Tororo District 
Hospital.  
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STUDY POPULATION AND SAMPLING 
Study population 
Our study population was all patients receiving anti-TB treatment from government sponsored 
health facilities within Tororo district. All the TB patients in Tororo district can receive free anti-
TB treatment either from Mukujju Health Center, Nagongera Health Center, or Tororo District 
Hospital. Sampling was not done since all the patients on anti-TB treatment with in government 
sponsored health facilities within Tororo were approached for inclusion in the study. A total 
number of 215 patients on anti-TB treatment for at least 2 months in Tororo district were 
approached to participate in the study. Of the 215 patients, 200 patients accepted to participate in 
the study, culminating into a response rate of 93%.  
Sampling 
There was no sampling as the total study population (the total TB population receiving anti-TB 
treatment from government sponsored health facilities within Tororo district) was approached to 
participate in the study. 
Thus, all patients who had been on anti-TB treatment for at least 2 months in government 
sponsored health facilities within Tororo district and were willing or whose parents (in case of 
children below 18 years) were willing to provide informed consent, were included in the study.  
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DATA COLLECTION AND ANALYSIS 
Data collection 
Data was collected by two trained research assistants through administering our pretested data 
instrument (questionnaire).  The questionnaire was pretested by administering it to three people 
who were not included in the main study. The pretesting of the questionnaire informed the 
researcher of ambiguous and repeated questions thus ambiguous questions were made clear and 
one of the repeated questions was deleted.  
The research assistants were chosen based on their ability to communicate in the local languages 
in Tororo in addition to English, their knowledge of data collection, and their experience of the 
cultures of the target population. The research assistants were fluent in English, Swahili, and either 
Ateso or Jopadhola.  
The questionnaires were translated to Swahili and retranslated back to English by another party to 
ensure that their meaning was retained. The questionnaires were administered in the TB clinic 
areas within the campuses of the three public health facilities (Two health facilities and one 
hospital). The questionnaires were administered as the patients (study participants) were waiting 
for their TB services such as anti-TB drug refills.  
The data collection process started with explaining the study to the patients or caretakers in case 
of children below 18 years of age.  Those who accepted to participate were moved away from the 
rest of the patients to a private place where no one else could hear the proceedings within or 
outside the TB clinic area. Patients were provided an information sheet which they read through 
followed by a detailed explanation of the purpose of the study, and were later asked to provide 
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informed consent before administration of the questionnaire commenced. Each participant was 
issued a unique study number which also appeared on their informed consent forms together with 
their names. Only participants’ unique study numbers were recorded on the questionnaires. No 
names were recorded on the questionnaires. A copy of the informed consent form was retained in 
a lockable cabin for reference. A list of prospective participants was provided by the health 
facilities’ officers in charge of anti-TB treatment.  A checklist was developed to track who had 
already been interviewed and who had not yet been interviewed to prevent duplication. The chief 
researcher did not administer questionnaires but double checked completeness of questionnaires 
completed by the research assistants.   
The data collection instrument 
We used a questionnaire as our data collection instrument to collect data from our study 
participants. The questionnaire was developed using the objectives of the study. Our data 
collection instrument was divided into six sections as listed below. 
 Section 100: General Information (Demographic and socioeconomic information).  
 Section 200: Access to information on TB 
 Section 300: Adherence factors 
 Section 400: Barriers to Adherence 
 Section 500: Perspective on benefits and/or costs of TB treatment  
 Section 600: Beliefs and myths about TB  
http://etd.uwc.ac.za/
 32 
 
Data analysis 
In this study, data was captured by the research assistants using Epi Info version 3.5.1. Data was 
then exported into and analyzed by the researcher using Microsoft Excel version 2010 for 
demographic and univariate analysis. We used Stata version 10.1 for bivariate analysis using the 
chi-square test and multivariate analysis using logistic regression (interactive expansive logistic 
regression). 
We graded participants who had history of missing one or more prescribed doses by the 
proportion of medication they swallowed in the last two weeks prior to the interview. We 
considered participants who had swallowed up to or more than 95% of their medication in the 
last two weeks prior to the interview as adherent to their anti-TB treatment. We considered 
participants who had swallowed less than 95% of their medication in the last two weeks prior to 
the interview as poorly adherent to their anti-TB treatment.  
We used measures of central tendency and measures of dispersion to describe the study 
variables.  We used the Chi-square test to ascertain the difference in the various independent 
variables’ anti-TB treatment adherent and poorly adherent proportions. We used interactive 
expansive logistic regression to ascertain the associations between adherence to anti-TB 
treatment and the different categories or levels of the various independent variables whose anti-
TB treatment adherent and poorly adherent proportions were found to be significantly different 
after univariate analysis.  
For statistical significance, we set and used the 5% level of significance as cut off. To describe 
and present the results, we used bar charts, pie charts, and tables. 
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VALIDITY AND RELIABILITY 
Validity  
Polit and Beck define validity as “the expression of the degree to which a test is capable of 
measuring what it is intended to measure” (Polit & Beck, 2008:768). Polit & Beck (2008) identify 
internal and external validity where internal validity is the degree to which the results of an 
observation are correct for the particular group of people being studied and external validity is the 
extent to which the results of a study apply to people not in it. We enhanced internal validity by 
using a cross sectional survey design which was the most appropriate design for our study purpose, 
we used a data collection tool that was pretested and adapted to our study, we complied with and 
observed our study protocols, and also ensured that our data collectors were not pre-exposed to the 
study area. External validity was ensured through carrying out a total population study which 
included all patients on TB treatment for at least 2 months in 3 different facilities in Tororo district 
(Tororo district government hospital, Mukujju health center, and Nagongera health center). This 
also increased the study statistical power and generalizability (Polit & Beck, 2008). In addition, 
the research assistants were trained on administering the questionnaires.   
Reliability  
Polit and Beck define reliability as “the degree of consistence or dependability with which an 
instrument measures an attribute” (Polit & Beck, 2008:764). To enhance reliability of our study 
data collection tool (questionnaire), it was pre-tested and adapted to our study. We also enhanced 
reliability by training research assistants on how to use the tool. To further ensure reliability, after 
translation of the questionnaires to Swahili, we had the questionnaire retranslated back to English 
by another party to check whether the meaning remained the same.  
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GENERALIZABILITY 
The study results are not generalizable to the whole country, but can be generalizable to people 
similar to our study participants and from settings similar to our study participants’ settings in 
Uganda or elsewhere in the world.  
ETHICAL CONSIDERATIONS  
Ethics approval to undertake this study was granted by the University of the Western Cape  Ethics 
Committee. Permission to collect data from patients in the three facilities Mukujju health center, 
Nagongera health center and Tororo hospital was granted by the Tororo District Local Government 
District Health Office. Participation was voluntary without any form of coercion. Information 
sheets explaining the study details, benefits, the study’s voluntary nature, and assurance of 
confidentiality and privacy were availed to the study participants in both English and Swahili and 
were explained further by the research assistants. Informed consent was sought and signed by 
patients who accepted to participate in the study. For minors (children below 18 years of age), 
consent was signed by their parents.  
Confidentiality and anonymity were enhanced by administering the questionnaire to one patient at 
a time in in a private area and in the absence of other participants. The identities of all participants 
were kept secret by using codes instead of participants' names, and all collected information was 
stored privately in a lockable cabinet. Participants who would have developed psychological or 
emotional harm would be referred to the health counsellor for assistance. Each participant was 
informed of his/her free will to withdraw from the study at any stage and no repercussion or 
consequence such with-holding TB care and treatment services would occur to him/her. The names 
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of the health facilities were not kept confidential because they are known to be providing TB 
services within the district.  
SCOPE AND LIMITATIONS OF THE STUDY 
We had some time and resource limitations but these did not affect the quality of our study. The 
opinions of health workers were not explored in this research study which could have added to the 
perspectives on anti-TB treatment. 
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CHAPTER FOUR: RESULTS 
In this chapter the results from the analysis of the factors associated with poor adherence to anti-
TB treatment in Tororo district is presented. The chapter starts with a description of the 
demographic characteristics of our study participants, followed by univariate and multivariate 
analysis. The study sample comprised 215 patients from the 3 health facilities with TB and 200 
(93%) were included in the final sample. The majority of the participants (53%) were recruited 
from Tororo District Hospital followed by Mukujju Health Center (30%) and the least number 
were from Nagongera Health Center (17%). 
DEMOGRAPHIC CHARACTERISTICS 
In this section of the results, the demographic characteristics including age, gender, marital 
status, household status, education level, occupation, type of water supply, and household 
electricity of the study sample are presented.  
Age, gender and household status 
The majority (74%) of the study participants were more than 45 years old and majority (60%) 
were female. The majority of the study participants (64%) were heads of their households, and 
the majority (62%) were married with only 0.5% cohabiting.  
Employment and education 
Most (80 – 40%) of our study participants attended secondary school education and 42 – 21% 
did not attend any education (Figure 1).  
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Figure 1: Education Level of TB patients on anti-TB treatment in Tororo District, 2016 (N=200). 
Most of the participants 92 – 46% were self-employed and only 9 – 4.5% were laborers (Figure 
2). 
 
Figure 2: Occupation of TB patients on anti-TB treatment in Tororo District, 2016 (N=200). 
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Environmental Characteristics 
Environmental characteristics of our study participants include type of water source, electricity 
supply, and living arrangements in terms of number of people participants live with, and number 
of rooms in the house.  
The majority (127 – 63.5%) of the study participants used bore holes as their water supply and 
only 2 – 1% used other types of water supply (Figure 3). The majority (135 – 67.5%) of the 
study participants, had no electricity supply in their houses.  
The majority of the study participants (180 – 90.5%) lived alone, 11 – 5.5% lived with family, 
only 1 – 0.5% lived with friends and 7 – 3.5% lived with other people.  The majority (88 – 
44.4%) of our study participants lived in houses with more than 3 bedrooms, 67 – 33.3% lived in 
3-bedroom houses, 43 – 21.7% lived in 2-bedroomed houses, and none lived in a one bedroom 
house. The majority (106 – 53.5%) of our study participants lived in a house of 4 – 6 people, 52 
– 26.3% lived in a house of less than or equal to 3 people, 30 – 15.2% lived in a house of 7 – 9 
people and 10 – 5.1% lived in a house of 10 or more people including themselves.  
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Figure 3: Type of water supply of TB patients on anti-TB treatment in Tororo District, 2016 
(N=200). 
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UNIVARIATE ANALYSIS 
We conducted univariate analysis on TB disclosure and HIV AIDS status, social economic 
factors, source of information on TB, adherence related factors, barriers to adherence, and beliefs 
and myths about TB. We used bar charts, pie graphs, and frequency tables to summarize and 
display the analysis results.  
Social economic factors 
The majority of the participants (157 – 78.5%) were permanent residents of Tororo district and 
the rest were temporary residents. Less than half of our study participants (81 – 40.5%) disclosed 
their average monthly income whose average was Uganda shillings (UGX) 222,035 with a 
standard deviation of Uganda shillings 229,512 and a range of Uganda shillings 5,000 to 
1,400,000. The majority of those who disclosed their monthly income (53 – 65.4%) were earning 
UGX 0 – 200,000, 22 – 27.2% were earning UGX 200,000 – 500,000 and only 6 – 7.4% were 
earning UGX 500,000 to 1,500,000.  
Substance use 
The majority of the participants (129 – 64.5%) never drank alcohol, only 1 – 0.5% drank more 
than 3 drinks a day, 5 – 2.5% drank less than 3 drinks a day, and 9 – 4.5% of the participants 
drank less than 5 drinks a week. Majority of the participants (180 – 90%) never smoked 
cigarettes, 16 – 8% occasionally smoked cigarettes, 3 – 1.5% regularly smoked less than 5 
cigarettes a week, and only 1 – 0 .5% regularly smoked more than 5 cigarettes a day. Except one 
participant who regularly smoked more than five cigarettes of marijuana a day, all other study 
participants never smoked Marijuana and none of our study participants used Cocaine.  
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Sources of information  
The majority of the participants (144 – 72%) received their information from health care workers 
followed by media (36 – 18%), relatives (10 – 5%), friends (5 – 2.5%) and others (4 – 2%). The 
least information source used by the participants was the TASO drama group with only (1 – 
0.5%) person reporting. The majority of the participants (181 – 90.5%) preferred information 
from health care workers followed by media (8 – 4%), relatives (3 – 1.5%), friends (2 – 1%), 
TASO drama group (2 – 1%), and others (4 – 2%). Most of the participants (89 – 44.5%) other 
preferred choice of information was media followed by relatives (46 – 23%), friends (40 – 20%), 
TASO drama group (14 – 7%), others (9 – 4.5%) and only 2 – 1% was booklets.   
The majority of our study participants (161 – 80.5%) have ever attended a TB awareness 
campaign and the rest have never. Among participants who attended awareness campaigns, 
Ministry of Health (MoH) Uganda provided TB awareness to 41 – 25.6% of the participants, 
NGOs provided to 12 – 7.7%, TASO drama group provided to 87 – 53.9%, and others provided 
to 21 – 12.8%.  
TB, HIV and AIDS disclosure status 
The majority of the participants (185 – 92.7%) had disclosed their TB status to someone and the 
rest did not. The majority of the participants (193 – 96.5%) knew their HIV status. Among 
participants who knew their HIV status, the majority 129 – 67.2% were HIV negative, 60 – 
31.3% were HIV positive, and 3 – 1.5% did not want to disclose their HIV status (Figure 6). The 
majority of the the participants (59 – 98.3%) who were HIV positive were also on anti-retroviral 
drugs (ART), and of these 19 – 32% were poorly adherent to anti-TB treatment. 
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ADHERENCE TO ANTI-TB TREATMENT 
In this section are univariate analysis results of various factors that include current anti-TB 
treatment, duration on anti-TB treatment, anti-TB treatment adherence status, reasons for missing 
doses, barriers to adherence, previous TB treatment, previous anti-TB treatment outcome, 
barriers to accessing drugs, barriers to taking medication, perspectives on TB, and knowledge 
beliefs and myths about TB.  
Current anti-TB treatment regimen and duration on anti-TB treatment 
The majority of the study participants (146 – 73%) were on 2HERZ/4HR or 2HERZ/6HE, 31 – 
15.5% were on the pediatric regimen (2HRZ/4HR), 20 – 10% were on 2SHERZ/1HERZ/5HER 
(retreatment regimen), and 2 – 1.0% were on other regimens which were both 2HERZ/10RH 
(Figure 4).  
 
Figure 4: Current anti-TB treatment regimen of TB patients on anti-TB treatment in Tororo 
District, 2016 (N=200). 
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Most of our study participants (76 – 38%) had swallowed their anti-TB drugs for 2 months and 
up to 71 – 35.5% had swallowed for more than 4 months (Figure 5).   
 
Figure 5: Duration on anti-TB treatment of TB patients on anti-TB treatment in Tororo District, 
2016 (N=200). 
Most of the participants (73 - 36.5%) swallowed 14 tablets a week, 67 - 33.5% swallowed 21 
tablets per week, 59 - 29.5% swallowed 28 tablets per week, and only 1 (0.5%) of the 
participants swallowed 35 tablets per week.  
For the majority of our study participants (165 – 82.5%), drug taking was monitored by 
someone. Most of the participants (87 – 43.5%) were monitored by their spouses, 38 - 19% were 
monitored by their mothers, 8 - 4% by their friends, 11 - 5.5% by their fathers, 6 - 3% by their 
siblings, 15 - 7.5% by others and 35 - 17.5% were not monitored.  
The majority of our study participants (180 - 90%), were not taking additional drugs apart from 
HIV drugs and rest did (Figure 9). The diseases that other drugs other than ARVs were taken for 
included Diabetes (1 participant), Hypertension (4 participants), and others (14 participants [who 
included Asthma, Malaria, Typhoid, Gastric ulcers, and a sexually transmitted infections]).  
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Anti-TB treatment adherence status 
Nearly two thirds of the participants (131 – 65%) were found to be adherent to their anti-TB 
treatment (Figure 6).  
 
 
Figure 6: Anti-TB treatment adherence status of TB patients on anti-TB treatment in Tororo 
District, 2016 (N=200). 
Reasons for missing medication  
Multiple reasons caused some participants to miss their drugs. Clinical reasons were cited by 
87% of the participants who missed their medication, and situation at home was cited by only 
30% of the participants who missed their medication (Figure 7).  
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Figure 7: Reasons for Missing Medication among TB patients on anti-TB treatment in Tororo 
District, 2016 (N=69).  
Barriers to Adherence 
The univariate analysis results of barriers to adherence to anti-TB treatment are as below. These 
include results of previous TB diagnosis, previous anti-TB treatment outcome, barriers to 
accessing drugs, perspectives on anti-TB treatment, and barriers to taking medication.  
Previous TB Diagnosis 
The majority of the study participants, (182 – 91%) had never been diagnosed with TB before, 
15 – 7.5% have ever been diagnosed with TB once before and 3 – 1.5% have ever been 
diagnosed with TB twice or more before. 
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The majority of our participants who received treatment before (28 – 53%) did not complete 
their treatment before. The reasons for not completing treatment included having to swallow too 
many pills (28%), pill taking length (8%), fear of getting anti-TB drugs side effects (24%), if 
participant vomits pills (8%), fear of people finding  out (4%)and others (N=169).  
 
Figure 8: Previous anti-TB Treatment Outcomes of TB patients on anti-TB re-treatment in 
Tororo District, 2016 (N=25). 
Barriers to Accessing Drugs 
Most of the study participants (80 – 40%) lived 2 – 4 kilometers from their TB treatment facility, 
most (85 – 43.1%) took averagely 30 – 60 minutes to pick their medication, majority 165 – 
82.5% required time off to pick their drugs, most (106 – 53%) used motor cycles as their travel 
means to pick their drugs, and majority (145 – 72.9%) had to pay for transport to pick their drugs 
(Table1).  
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Table 1: Barrier to accessing drugs among TB patients on anti-TB treatment in Tororo District, 
2016 
Barrier to accessing 
drugs 
Degree of barrier to accessing drugs Number (%)  
Distance between 
hospital and home 
< 2 km 44(22%) 
2 – 4 km 80(40%) 
4 – 6 km 45(23%) 
6 – 8 km 12(6%) 
8 – 10 km 4(2%) 
> 10 km 15 (8%) 
Total 200 
Average time to move to 
and back from the 
hospital 
<30 minutes 51(26%) 
30 – 60 minutes 85(43%) 
60 – 90 minutes 37(19%) 
90 – 120 minutes 10(5%) 
>120 minutes, Specify  14(7%) 
Total 197 
Time off to pick drugs No need to take off time to pick my drugs 35(18%) 
Need to take off time to pick my drugs 165(83%) 
Total 200 
Travel means to pick 
drugs 
Bicycle 23(12%) 
Car 16 (8%) 
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Mini-Bus 8(4%) 
Motor cycle 106(53%) 
Walk 47(24%) 
Total 200 
Having to pay transport No 54(27%) 
Yes 145(73%) 
Total 199 
 
Barriers to Taking Medication  
Almost all our study participants (193 – 98.5%) did not have history of any Psychiatric illness, 
170 – 85.4% had no history of difficulties in swallowing their drugs, and 152 – 77% did not have 
history of feeling stigmatized because of TB. The majority of our study participants (115 – 58%) 
did experience a side effect of anti-TB treatment.   
Most of the study participants 57 – 28.5% would most likely want to quit their anti TB treatment 
because of too many pills and only 19 - 9.5% would want to quit because of pill taking length 
(Figure 9).   
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Figure 9: Reasons to quit anti-TB medication among TB patients on anti-TB treatment in Tororo 
District, 2016 (N=200). 
Perspectives on TB 
Here are the results of the perspectives on stopping anti-TB drugs, perspectives on taking drugs 
as prescribed, perspectives on benefits or costs of TB treatment, and perspectives on TB 
acquisition.  
Perspectives on stopping anti-TB drugs  
The majority of the participants (166 – 83%) thought that they can feel worse or TB could 
worsen if they stopped swallowing their anti-TB drugs and only 1 – 0.5% thought nothing would 
happen (Figure 10).  
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Figure 10: Perspectives on stopping anti-TB drugs among TB patients on anti-TB treatment in 
Tororo District, 2016 
Perspective on taking drugs as prescribed for 6 – 8 months  
As per the perspective on taking drugs as prescribed for 6 – 8 months, the majority of the 
participants, 195 – 97.5% admitted that they would take drugs as prescribed (Figure 11).  
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Figure 11: Perspective on ramifications if anti-TB drugs are stopped among TB patients on anti-
TB treatment in Tororo District, 2016 (N=200). 
Perspective on the benefits and/or costs of TB treatment 
Most of the participants strongly agreed with almost all of the positive perspectives on benefits 
and/or costs of TB treatment in our study (Table 2).  
Table 2: Perspective on the benefits and/or costs of TB treatment among TB patients on anti-TB 
treatment in Tororo District, 2016 
Perspectives on benefits and/or costs of 
TB treatment 
Strongly 
agree 
Agree Don’t 
know 
 Disagree 
Taking anti-TB drugs outweigh any 
difficulties. 
72(36%) 124(62%) 2(1%) 2(1%) 
Taking anti-TB drugs is too cumbersome 108(54%) 81(40.5%) 3(1.5%) 8(4%) 
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Taking anti-TB drugs is better than not 
taking them. 
134(66.8%) 62(70%) 1(0.5%) 4(2%) 
Taking anti-TB drugs will help me be 
healthy. 
143(71.5%) 56(28%) 1(0.5%) 0(0%) 
No improvement if treatment plan is not 
followed. 
133(66.5%) 59(29.5)% 5(2.5%) 3(1.5%) 
TB is life threatening. 144(72%) 51(25.5%) 5(2.5%) 0(0%) 
TB can worsen HIV/AIDS. 107(53.5%) 57(28.5%) 35(17.5%) 1(0.5%) 
Taking drugs poorly can lead to TB 
complications 
143(71.5%) 51(25.5%) 6(3%) 0(0%) 
 
Perspectives on how participants acquired TB 
The majority (124 – 62.0%) of the participants thought TB is acquired through cough of a case, 
and almost a third of the participants did not know how TB is acquired (Figure 12).  
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Figure 12: Perspectives on TB acquisition among TB patients on anti-TB treatment in Tororo 
District, 2016 (N=200). 
Knowledge, beliefs and myths about TB 
The majority of the participants were well knowledgeable on beliefs and myths about TB and 
anti-TB treatment (Table 3).   
Table 3: Knowledge and beliefs about TB among TB patients on anti-TB treatment in Tororo 
District, 2016 
Knowledge, beliefs and 
myths about TB 
Strongly 
agree 
Agree Don’t 
Know 
Disagree Strongly 
Disagree 
Traditional healers can 
help heal TB. 
4(2.0%) 8(4.0%) 28(14.0%) 55(27.5%) 105(52.5%) 
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TB can cure without 
completing anti-TB 
treatment. 
10(5.0%) 3(1.5%) 4(2.0%) 72(36.2%) 111(55.3%) 
TB can be transmitted 
through the air 
83(41.5%) 85(42.5%) 23(11.5%) 8(4.0%) 1(0.5%) 
Congestion and poor 
circulation increase TB 
transmission 
65(32.5%) 93(46.5%) 33(16.5%) 8(4.0%) 1(0.5%) 
Completing anti-TB 
treatment is vital for TB 
cure 
97(48.5%) 91(45.5%) 8(4.0%) 4(2.0%) 0(0.0%) 
After initial two weeks of 
regularly swallowing anti-
TB drugs, TB 
transmission to family 
decreases 
65(32.5%) 98(49.0%) 28(14.0%) 7(3.5%) 2(1.0%) 
I have to swallow anti-TB 
drugs for 6 or 8 months 
142(71.0%) 49(24.5%) 3(1.5%) 1(0.5%) 4(2.0%) 
Timing of doses 
medication influences 
effectiveness 
103(51.3%) 81(40.7%) 5(2.5%) 8(4.0%) 3(1.5%) 
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Incorrect swallowing of 
drugs can ruin treatment 
outcome 
108(54.0%) 81(40.5%) 3(1.5%) 2(1.0%) 6(3.0%) 
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BIVARIATE ANALYSIS  
Bivariate (Chi square test) Results  
We conducted bivariate analysis of various factors that we presumed to be associated with poor 
adherence to anti-TB treatment by anti-TB treatment status. Among these factors are 
demographic factors, social economic factors, factors related to source of information on TB, 
adherence related factors, barriers to adherence factors, and factors related to beliefs and myths 
about TB. We used the Chi-square test. The results are displayed in two by two tables and a p-
value of 0.05 was used to decide significance of the factors depending on results. The bivariate 
analysis results of the factors presumed to be associated with poor adherence to anti-TB 
treatment are shown below.  
Demographic factors  
Results of bivariate analysis of various demographic factors by anti TB treatment status are 
shown below displayed in two by two tables, summarized in percentages with p-values.  
Age by sex and anti-TB treatment adherence status  
Most of the poorly adherent participants (14 – 74%) were more than 45 years old and were 
female (Table 4). 
Table 4: Age and gender of TB patients on anti-TB treatment by adherence status in Tororo 
District, 2016 
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Age group Adherent by gender N (%) Poorly Adherent by gender N 
(%) 
 
Female Male Female Male 
<18 Years 3(38%) 5(63%) 1(33%) 2(67%) 
18-25 Years 16(55%) 13(45%) 7(50%) 7(50%) 
26-35 Years 14(61%) 9(39%) 9(50%) 9(50%) 
36-45 Years 22(67%) 11(33%) 8(53%) 7(47%) 
> 45 Years 27(71%) 11(29%) 14(74%) 5(26%) 
Total 82(63%) 49(37%) 39(57%) 30(43%) 
 
Marital status, household status, type of water source, and occupation by anti-TB 
treatment adherence status 
Marital status, household status, type of water source, and occupation were not found significant 
with p-values of 0.187, 0.588, 0.862, and 0.135 respectively. 
Education level by anti-TB treatment adherence status 
Among the participants who attended secondary education, 23(29%) were poorly adherent to anti 
TB treatment and participants who did not attended any education, only 15 (36%) were poorly 
adherent to anti TB treatment. This had no significant difference to the adherent group with a p-
value of 0.539 (Table 5). 
Table 5: Education level by anti-TB treatment adherence status among TB patients on anti-TB 
treatment in Tororo District, 2016 
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Education level Adherent N (%) Poorly adherent N (%) Total  
No education 27(64%) 15(36%) 42 
Primary 31(61%) 20(39%) 51 
Secondary 57(71%) 23(29%) 80 
Post-Secondary 16(59%) 11(41%) 27 
Total   200 
Pearson chi2(3) =   2.1651   Pr = 0.539 
Presence of electricity in the house by anti-TB treatment adherence status 
Among the participants who had electrical supply in the house, 30 – 46% were poorly adherent. 
This was a significant difference from the adherent group with a p-value of 0.016 (Table 6).  
Table 6 : House hold electricity by anti-TB treatment adherence status among TB patients on 
anti-TB treatment in Tororo District, 2016 
House hold electricity Adherent N (%) Poorly adherent N (%) Total 
Yes 35(54%) 30(46%) 65 
No 96(71%) 39(29%) 135 
Total     200 
Pearson chi2(1) =   5.7875   Pr = 0.016 
Social economic factors by anti-TB treatment adherence status 
Results of bivariate analysis of various socio-economic factors by anti TB treatment status are 
shown below displayed in two by two tables, and summarized by percentages with p-values.  
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Residence status in Tororo district by anti-TB treatment adherence status 
Among the considerable number of the participants who were permanent residents in Tororo 
district, 58 – 37% were poorly adherent to anti-TB treatment. This was not significant with a p-
value of 0.165.  
Knowledge of HIV status, HIV status and TB status disclosure by anti-TB treatment 
adherence status 
More than half of the participants who did not want to disclose their HIV status, 2 – 67% were 
poorly adherent to treatment, an insignificant difference from the adherent group with a p-value 
0.440. A bigger proportion of participants who revealed their TB status to their fathers (14 – 
54%) were poorly adherent to their anti-TB treatment, an insignificant difference from the 
adherent group with a p-value 0.180 (Table 7).  
Table 7: Knowledge of HIV status, HIV status disclosure, and TB status disclosure by anti-TB 
treatment adherence status among TB patients on anti-TB treatment in Tororo District, 2016 
 
Knowledge of HIV status, 
HIV status disclosure, and 
TB status disclosure  
Status/Level 
/Degree  
Adherent N 
(%) 
Poorly 
adherent N 
(%) 
P-
value 
Knew their HIV status Yes 125(65%) 68(35%) 0.737 
No 5(71%) 2 (29%) 
HIV Status Positive 41(68%) 19(32%) 0.440 
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Negative 83(64%) 46(36%) 
Did not want to 
disclose 
1(33%) 2(67%) 
Disclosed TB status Yes 122(66%) 63(34%) 0.477 
No 8(57%) 6(43%) 
Person to whom 
participant disclosed TB 
status to 
Spouse 75(69%) 33(31%) 0.180 
Father 12(46%) 14(54%) 
Mother 20(74%) 7(26%) 
Sibling 5(63%) 3(38%) 
Friend 4(50%) 4(50%) 
Other 11(79%) 3(21%) 
 
Monthly income by anti-TB treatment adherence status 
The average income of our participants was 222,035 Uganda shillings with a standard deviation 
of 229512 Uganda shillings. Among the participants who were earning between UGX 500,000 to 
1,500,000 category, 3 – 50% were poorly adherent to their anti-TB treatment. This was not 
significant with a p-value of 0.736 (Table 8).  
Table 8: Monthly income by anti-TB treatment adherence status among TB patients on anti-TB 
treatment in Tororo District, 2016 
Participants’ Average monthly 
income 
Adherent N 
(%) 
Poorly adherent N 
(%) 
Total 
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UGX 0 – 200,000 33(62%) 20(38%) 53 
UGX 200,000 – 500,000 12(55%) 10(45%) 22 
UGX 500,000 – 1,500,000 3(50%) 3(50%) 6 
Total   81 
Pearson chi2(2) =   0.6138   Pr = 0.736 
House Living conditions by anti-TB treatment adherence status 
Person/s the participants live with, number of people living in the house, number of bedrooms in 
the house by anti-TB treatment adherence status, had no significance found between TB 
medication adherent and non-adherent participants with p-values of 0.155, 0.558 and 0.676 
respectively. 
Drug use by anti-TB treatment adherence status  
Alcohol consumption, cigarette smoking and marijuana smoking had no significance found 
between TB medication adherent and non-adherent participants with p-values of 0.413, 0.578, 
and 0.167 respectively.  
Access to Information on TB by anti-TB treatment Status 
Results of bivariate analysis of various factors to do with access to information on TB by anti TB 
treatment status are shown below displayed in two by two tables and summarized into 
percentages with p-values.  
Main Source of information by anti-TB treatment adherence status 
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The only participant whose source of information was TASO drama group was poorly adherent 
to anti-TB treatment while 52 – 36% of those whose source of information was health workers 
were poorly adherent, a non-significant difference compared to the adherent group with a p-value 
of  0.470 (Table 9).  
Table 9: Main Source of information by anti-TB treatment adherence status among TB patients 
on anti-TB treatment in Tororo District, 2016 
Main Source of information Adherent N (%) Poorly adherent N (%) Total 
Media 25(69%) 11(31%) 36 
Health workers 92(64%) 52(36%) 144 
Relatives 7(70%) 3(30%) 10 
Friends 3(60%) 2(40%) 5 
TASO Drama group 0(0%) 1(100%) 1 
Other 4(100%) 0(0%) 4 
Total   200 
Pearson chi2(5) =   4.5752   Pr = 0.470 
Preferred choice of information by anti-TB treatment adherence status 
All the participants 2 – 100% whose preferred choice of information was TASO Drama group 
were poorly adherent to their anti-TB treatment with an insignificant difference to the adherent 
group of a p-value of 0.061 (Table 10).  
Table 10: Preferred choice of information by anti-TB treatment adherence status among TB 
patients on anti-TB treatment in Tororo District, 2016 
http://etd.uwc.ac.za/
 63 
 
Preferred choice of information Adherent N (%) Poorly adherent N (%) Total 
Media 3(38%) 5(63%) 8 
Health workers 121(67%) 60(33%) 181 
Relatives 1(33%) 2(67%) 3 
Friends 1(50%) 1(50%) 2 
TASO Drama group 0(0%) 2(100%) 2 
Other 4(100%) 0(0%) 4 
Total     200 
Pearson chi2(5) =  10.5559   Pr = 0.061 
History of attending any TB awareness campaign by anti-TB treatment adherence status 
Among the participants who ever attended a TB awareness campaign, 58 – 36% were poorly 
adherent to anti-TB treatment. This had no significant difference with a p-value of 0.512 (Table 
11).  
Table 11: History of attending any TB awareness campaign by anti-TB treatment adherence 
status among TB patients on anti-TB treatment in Tororo District, 2016 
History of attending any TB 
awareness campaign 
Adherent N (%) Poorly adherent N (%) Total 
Ever attended 103(64%) 58(36%) 161 
Never attended 28(72%) 11(28%) 39 
Total 
  
 200 
Pearson chi2(1) =   0.4309   Pr = 0.512 
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Adherence factors by anti-TB treatment status  
Results of bivariate analysis of various adherence factors by anti TB treatment status are shown 
below displayed in two by two tables and summarized into percentages with p-values.  
TB regimen participant taking currently by anti-TB treatment adherence status 
The majority of participants on retreatment regimen (13 – 65%) were poorly adherent to their 
anti-TB treatment with a significant difference to the adherent group of a p-value of 0.026 (Table 
12).  
Table 12: TB regimen participant taking currently by anti-TB treatment adherence status among 
TB patients on anti-TB treatment in Tororo District, 2016 
TB regimen on currently Adherent N (%) Poorly adherent N (%) Total 
2HERZ/4HR or 2HERZ/6HE 100(68%) 47(32%) 147 
2HRZ/4HR 22(71%) 9(29%) 31 
2SHERZ/1HERZ/5HER 7(35%) 13(65%) 20 
Others 2(100%) 0(0%) 2 
Total     200 
Pearson chi2(3) =   9.2240   Pr = 0.026 
Duration on anti-TB treatment by anti-TB treatment adherence status 
Among the participants who had swallowed their anti-TB treatment for 2 months 30 – 39% were 
poorly adherent. This was not significant with a p-value of 0.716 (Table 13). 
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Table 13: Duration on anti-TB treatment by anti-TB treatment adherence status among TB 
patients on anti-TB treatment in Tororo District, 2016 
Duration on anti-TB treatment Adherent N (%) Poorly adherent N (%) Total 
2 months 46(61%) 30(39%) 76 
3 months 20(67%) 10(33%) 30 
4 months 16(70%) 7(30%) 23 
> 4 months 49(69%) 22(31%) 71 
Total   200 
Pearson chi2(4) =   2.1050   Pr = 0.716 
Number of Tablets swallowed per week by anti-TB treatment adherence status 
Among the participants who swallowed 28 tablets a week, 24 – 41% were poorly adherent to 
anti-TB treatment. There was no significant difference with a p-value of 0.443 (Table 14). 
Table 14: Number of Tablets swallowed per week by anti-TB treatment adherence status among 
TB patients on anti-TB treatment in Tororo District, 2016 
Number of Tabs swallowed 
per week 
Adherent N (%) Poorly adherent N (%) Total 
14 tablets 47(64%) 26(36%) 73 
21 tablets 48(72%) 19(28%) 67 
28 tablets 35(59%) 24(41%) 59 
 35 tablets  1(100%) 0(0%) 1 
 Total   200 
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Pearson chi2(3) =   2.6819   Pr = 0.443 
Monitoring of drug taking by someone by anti-TB treatment adherence status 
Among the participants whose drug taking was monitored 59 – 36% were poorly adherent and 
106 – 64% were adherent. And of those whose drug taking was not monitored, 10 – 29% were 
poorly adherent and 25 – 71% were adherent. This was not significant with a p-value of 0.417. 
Perspective of what may happen if the participants stop taking drugs by anti-TB treatment 
adherence status 
Among the participants who were not sure about what would happen if they stopped taking their 
anti-TB treatment, 6 – 60% were poorly adherent This had no significant difference with a p-
value of 0.398 (Table 15).  
Table 15: Perspective of what may happen if the participants stop taking drugs by anti-TB 
treatment adherence status among TB patients on anti-TB treatment in Tororo District, 2016 
Perspective if the participants 
stopped taking drugs 
Adherent N (%) Poorly adherent N (%) Total 
Not Sure  4 (40%) 6 (60%) 10 
Nothing would happen 1(0.5%) 0(0%) 1 
Feel worse or TB could worsen 111 (67%) 55 (33%) 166 
Develop complications 9 (60%)  6 (40%) 15 
Pills stop working 6 (75%) 2 (25%) 8 
Total     200 
Pearson chi2(4) =   4.0619   Pr = 0.398 
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Barriers to Adherence 
Here are bivariate analysis results of barriers to anti-TB treatment by anti-TB treatment status. 
These included number of times diagnosed with TB, history of completing treatment if 
previously diagnosed, perspective on taking pills as prescribed for 6 or 8 months, Distance of 
health facility from home, average time to move to and from hospital to pick drugs, requirement 
of time off to pick drugs, means of travel to pick drugs, requirement to pay transport fare to get 
to the health facility, history of treatment for a Psychiatric illness, any difficulties in taking TB 
drugs regularly and on time, any stigmatization because of having TB, what would cause then to 
quit taking your TB drugs, and experience of any TB drugs side effects.  
Number of times participant diagnosed with TB before current diagnosis time by anti-TB 
treatment adherence status 
Among the participants who had never been diagnosed with TB before, 60 (33%) were poorly 
adherent to anti- TB treatment, and of those who had ever been diagnosed with TB once, 60% 
were poorly adherent. This had a significant difference with a p-value less than 0.048 (Table 16).  
Table 16: Number of times participant diagnosed with TB before current diagnosis time by anti-
TB treatment adherence status among TB patients on anti-TB treatment in Tororo District, 2016 
Number of times diagnosed with 
TB before current diagnosis time 
Adherent N (%) Poorly adherent N (%) Total 
Never 122(67%) 60(33%) 182 
Once 6(40%) 9(60%) 15 
Twice or more 3(100%) 0(0%) 3 
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Total 
 
  200 
Pearson chi2(3) =   6.0857   Pr = 0.048 
Previous anti-TB Treatment outcome by anti-TB treatment adherence status 
Among the participants who completed treatment, 12 – 48% were poorly adherent to treatment 
and of those who did not complete treatment, 10 – 36% were poorly adherent. This was not 
statistically significant with a p-value of 0.365 (Table 17).   
Table 17: Previous anti-TB Treatment outcome by anti-TB treatment adherence status among TB 
patients on anti-TB treatment in Tororo District, 2016 
Previous anti-TB Treatment 
outcome 
Adherent N (%) Poorly adherent N (%) Total 
Completed treatment before 13(52%) 12(48%) 25 
Never completed treatment before 18(64%) 10(36%) 28 
Total  31(58%)  22(42%) 53 
Pearson chi2(1) =   0.8211   Pr = 0.365 
Perspective on Taking pills as prescribed for 6 – 8 months 
All the participants 5 – 2.5% with a perspective of not taking drugs as prescribed were poorly 
adherent to their anti-TB treatment. This was significant with a p-value of 0.002 (Table 18).  
Table 18: Perspective on Taking pills as prescribed for 6 – 8 months among TB patients on anti-
TB treatment in Tororo District, 2016 
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Perspective on Taking pills as 
prescribed for 6 – 8 months 
Adherent N (%) Poorly adherent N (%) Total 
Could take as prescribed 131(67%) 64(33%) 195 
Could not take as prescribed 0(0%) 5(100%) 5 
Total     200 
Pearson chi2(1) =   9.7362   Pr = 0.002  
 
Barriers to accessing drugs by anti-TB treatment status 
Distance between health facility and home, average time to move to and back from the health 
facility, need of time off to pick anti-TB drugs, travel means to pick drugs by anti-TB treatment 
adherence status, and having to pay for transport to pick medication were all found with no 
significance between the TB treatment adherent participants and non-adherent participants with 
p-values of 0.517, 0.523, 0.417, 0.730, and 0.854 respectively. 
History of Psychiatric illness by anti-TB treatment adherence status 
Among those who did not have history of psychiatric illness, 66 – 34% were poorly adherent and 
of those who had history of psychiatric illness 1 – 33% was poorly adherent. This had no 
significance difference to the adherent group with a p-value of 0.975. 
History of difficulty in swallowing drugs by anti-TB treatment adherence status 
Among the participants who had difficulty in swallowing their drugs, 16 – 55% were poorly 
adherent. This was significant with a p-value of 0.012 (Table 19).  
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Table 19: History of difficulty in swallowing drugs by anti-TB treatment adherence status among 
TB patients on anti-TB treatment in Tororo District, 2016 
History of difficulties in 
swallowing drugs 
Adherent N (%) Poorly adherent N (%) Total 
No history of difficulties 117(69%) 53(31%) 170 
History of difficulties 13(45%) 16(55%) 29 
Total     199 
Pearson chi2(1) =   6.2977   Pr = 0.012 
What could most likely make a participant want to quit their anti-TB drugs by anti-TB 
treatment adherence status?  
A higher proportion of participants (29 – 51%) believed that having to swallow too many pills 
would make them want to quit their anti-TB medication were poorly adherent to their anti TB 
treatment. This was significant with a p-value of 0.003 (Table 20). 
Table 20: What could most likely make a participant want to quit their anti-TB drugs by anti-TB 
treatment adherence status among TB patients on anti-TB treatment in Tororo District, 2016 
What could make participants want to 
quit swallowing their anti-TB drugs 
Adherent N 
(%) 
Poorly adherent 
N (%) 
Total 
Pill taking length 15(79%) 4(21%) 19 
Too many pills 28(49%) 29(51%) 57 
If I vomit my pills 15(68%) 7(32%) 22 
If I get anti-TB drugs side effects 28(88%) 4(13%) 32 
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Fear people finding out my status 21(75%) 7(25%) 28 
Other, Specify    24(57%) 18(43%) 42 
Total     200 
Pearson chi2(5) =  17.6261   Pr = 0.003 
History of experiencing any side effects and history of feeling stigmatized 
Among the participants 115 who experienced side effects, 44 – 38% were poorly adherent and of 
those who had history of feeling stigmatized, only 15 – 33% were poorly adherent.  This was not 
significant with a p-value of 0.560 (Table 21). The side effects experienced included but not 
limited to burning of the feet 69 – 60%, nausea and vomiting 25 – 22%, visual impairment 11 – 
10%, skin rashes 4 – 3%, deafness 3 – 3%; and swelling of the breasts, decreased urine put and 
others all making 3 – 2%.  
Table 21: History of experiencing any side effects and feeling stigmatized by anti-TB treatment 
adherence status among TB patients on anti-TB treatment in Tororo District, 2016 
Factor Status of 
Factor  
Adherent N 
(%) 
Poorly adherent N 
(%) 
P-value 
History  of experiencing any 
side effects 
Yes  71(62%) 44 (38%) 0.193 
No 60(71%) 25 (29%)  
History of feeling 
stigmatized because of TB 
Yes 31(67%) 15(33%) 0.777 
No 53(35%) 99 (65%)  
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Perceptions on acquisition of TB by anti-TB treatment adherence status 
Among our participants who were not sure of the way they acquired TB, 29 – 45% were poorly 
adherent to anti-TB treatment. This was non-significant with a p-value of 0.110 (Table 22).  
Table 22: Perceptions on acquisition of TB by anti-TB treatment adherence status among TB 
patients on anti-TB treatment in Tororo District, 2016 
Perceptions on acquisition of TB Adherent N (%) Poorly adherent N (%) Total 
Not sure / don't know 35(55%) 29(45%) 64 
Being bewitched 1(100%) 0(0%) 1 
Cigarette smoking 9(90%) 1(10%) 10 
Hospital 1(100%) 0(0%) 1 
Through cough of a case 86(69%) 38(31%) 124 
Total 
 
  200 
Pearson chi2(4) = 7.5307 Pr = 0.110 
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Bivariate (Logistic Regression) Results  
In this section are the bivariate analysis results of the factors that were found to have significant 
differences in their proportions on chi square test. This was done using interactive expansive 
logistic regression at a set p-value of < 0.05. Participants who had electricity in their houses were 
significantly associated with poor adherence to anti-TB treatment with an un-adjusted Odds ratio 
(OR) of 2.109 and a p-value of 0.017. Participants who experienced difficult in swallowing their 
drugs were significantly associated with poor adherence to anti-TB treatment with an un-adjusted 
OR of 2.717 and a p-value of 0.014. Participants who were on second line adult anti-TB 
treatment were significantly associated with poor adherence with an un-adjusted Odds ratio (OR) 
of 3.95 and a p-value of 0.006. Participants who had history of having been diagnosed with TB at 
least once before were significantly associated with poor adherence to anti TB treatment with an 
un-adjusted OR of 3.05 and a p-value of 0.04. Participants who thought that taking too many 
pills would make them quit their anti TB drugs were significantly associated with poor adherence 
to anti-TB treatment with an un-adjusted OR of 3.88 and a p-value of 0.029. Participants who 
agreed  that the benefits of taking anti-TB drugs outweighs any difficulties they may encounter 
were significantly less likely to be poorly adherent with an un-adjusted OR of 0.51 and a p-value 
of 0.030. Participants who agreed that missing doses or taking them incorrectly can ruin their 
treatment outcome were significantly likely to be poorly adherent with an un-adjusted OR of 
2.41 and p-value of 0.005. Participants who did not know that TB can be transmitted through the 
air were significantly less likely to be poorly adherent with an un-adjusted OR of 0.26 and a p-
value of 0.024 (Table 23).  
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MULTIVARIATE ANALYSIS 
In this section are multivariate analysis results of factors that were found to be significantly 
associated with poor adherence to anti TB treatment after bivariate analysis using chi square test 
and interactive expansive logistic regression. This multivariate analysis was also done using 
interactive expansive logistic regression at a set p-value of 0.05.  
Participants who had electricity in their houses were significantly independently associated with 
poor adherence to anti-TB treatment with an adjusted Odds ratio (OR) of 2.22 and a p-value of 
0.045. Participants who were on second line adult anti-TB treatment were significantly 
independently associated with poor adherence with an adjusted Odds ratio (OR) of 3.39 and a p-
value of 0.049. Participants who had history of having been diagnosed with TB at least once 
before were significantly independently associated with poor adherence to anti TB treatment 
with an adjusted OR of 3.94 and a p-value of 0.045. Participants who thought that taking too 
many pills would make them quit their anti TB drugs were independently associated with poor 
adherence to anti-TB treatment with an adjusted OR of 6.54 and a p-value of 0.010. Participants 
who agreed that missing doses or taking them incorrectly can ruin their treatment outcome were 
independently likely to be poorly adherent with an adjusted OR of 2.57 and p-value of 0.013 
(Table 23).  
Experiencing difficulties in swallowing drugs, not knowing that  the benefits of taking anti-TB 
drugs outweighs any difficulties that may be encountered, and not knowing / disagreeing that  
TB can be transmitted through the air were not independently associated with poor adherence to 
anti-TB treatment (Table 23). 
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Table 23: A summary of bivariate and multivariate analysis results from logistic regression of 
factors associated with poor adherence to anti-TB treatment among TB patients on anti-TB 
treatment in Tororo District, 2016 
Variable Gradation/level Number 
(N) 
Un - 
AOR 
P-
Value 
AOR P-
Value 
House hold 
electricity 
No  135 1.00   1.00   
Yes 65 2.11 0.017 2.22 0.045 
Difficulties in 
swallowing 
No  170 1.00  1.00  
Yes 29 2.72 0.014 2.55 0.056 
TB Regimen 2HERZ/4HR or 
2HERZ/6HE 
147 1.00  1.00  
2HRZ/4HR 31 0.87 0.749 0.44 0.125 
2SHERZ/1HERZ/5HER 20 3.95 0.006 3.39 0.049 
Other  2 -  -  
Number of previous 
TB diagnoses 
Never 182 1.00  1.00  
Once 15 3.05 0.043 3.94 0.045 
Twice or more 3 -  -  
What would make a 
participant want to 
Pill taking length 28 1.00  1.00  
Too many pills 42 3.88 0.029 6.54 0.010 
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quit taking anti-TB 
drugs 
If I vomit my pills 22 1.75 0.440 1.21 0.820 
anti-TB drugs side effects 57 0.53 0.421 0.97 0.973 
Fear people discovering 
my status 
19 1.25 0.754 1.59 0.567 
Other 32 2.81 0.108 2.47 0.228 
Benefits of taking 
anti-TB drugs 
outweighs any 
difficulties 
encountered 
Strongly agree 72 1.00  1.00  
Agree 124 0.51 0.030 0.88 0.757 
Don’t know 2 1.25 0.876 1.32 0.852 
Disagree 0 -  -  
Strongly disagree 0 -  -  
Missing doses or 
taking them 
incorrectly can ruin 
treatment  outcome 
Strongly agree 108 1.00  1.00  
Agree 81 2.41 0.005 2.57 0.013 
Don’t Know 0 -  -  
Disagree 0 -  -  
Strongly disagree 6 1.36 0.729 1.21 0.849 
TB can be 
transmitted through 
the air 
Strongly agree 83 1.00  1.00  
Agree 85 0.55 0.062 0.67 0.349 
DK 23 0.26 0.024  0.35 0.134 
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Disagree 8 0.41 0.298 0.92 0.928 
Strongly disagree 0 -  -  
N = 200,  
- = Dropped (less than 5 observations in a cell) 
CONCLUSION 
This chapter presented the research findings and interpretation from our study’s data analysis. 
It’s clear that possessing electricity in the house, being on second line adult anti-TB treatment, 
history of having been diagnosed with TB at least once before, thoughts that taking too many 
pills would cause quitting anti TB drugs, and agreeing that missing doses or taking them 
incorrectly can ruin treatment outcome were independently associated with poor adherence to 
anti-TB treatment with p-values of < 0.05. On the contrary, experiencing difficulties in 
swallowing drugs, agreeing that  the benefits of taking anti-TB drugs outweighs any difficulties 
that may be encountered, and not knowing that  TB can be transmitted through the air were not 
independently associated with poor adherence to anti-TB treatment.  
The next chapter will discuss the findings and their interpretations relating to published literature 
in order to draw conclusions and recommendations in the final chapter.  
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CHAPTER FIVE: DISCUSSION 
INTRODUCTION 
In this chapter is presented the discussion of our study results in relation to our study aims and 
objectives which were; - to describe the socio-demographic profiles of persons on anti-TB 
treatment, to determine the extent of poor adherence to anti-TB treatment, and to identify factors 
that influence TB treatment adherence among persons on anti TB Treatment for at least 2 months 
in Tororo district. As we focus on our study objectives through the discussion, we compare our 
results to already published literature from which we draw our chapter on conclusions and 
recommendations accordingly.  
SOCIO-DEMOGRAPHIC PROFILES OF PERSONS ON ANTI TB TREATMENT IN 
TORORO DISTRICT 
Our study participants were mainly males (60.5%) than females. The lack of gender balance 
which was not due to inclusion because we enrolled all patients who could accept to participate 
in the study, was due to the fact that more males were affected by Tuberculosis than females. 
This is commensurate with Adane et al ( 2013) and WHO (2016) who also reveal the male 
gender to be more affected by Tuberculosis than the female gender (Adane et al., 2013; WHO, 
2016).  
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EXTENT OF POOR ADHERENCE TO ANTI-TB TREATMENT IN TORORO 
DISTRICT 
Our study results clearly revealed that up to a third (34.5%) of the patients on anti-TB treatment 
in Tororo district were poorly adherent to their anti-TB medication. This is more than what was 
revealed from a literature review of four different manuscripts in sub-Saharan Africa that 
revealed a proportion of 11.3% to 29.6% of patients on anti-TB treatment to have defaulted 
treatment (Castelnuovo, 2010) but close to a retrospective study in Southern India that found 
33% of the patients on anti-TB treatment to be poorly adherent (Gopi et al., 2007).  
FACTORS ASSOCIATED WITH POOR ADHERENCE TO ANTI-TB TREATMENT IN 
TORORO DISTRICT 
Participants who had a once previous diagnosis of TB were almost 4 times more likely to be 
poorly adherent to their anti-TB treatment as compared to participants who had never been 
diagnosed with TB before in an independent association with a p-value of 0.045. This is 
consistent with a study conducted in South Africa where patients who had defaulted on TB 
treatment before were found to default their anti-TB treatment (Finlay et al., 2012).  
The likelihood of poor adherence to anti-TB treatment was also 6 times more likely for 
participants who believed that having to swallow too many pills would cause them to quit their 
anti-TB treatment in an independent association with a p-value of 0.010. This is in agreement 
with a study conducted in Ethiopia which found having to swallow very many pills to be one of 
the reasons for poor adherence to anti-TB treatment (Nezenega et al., 2013). More to this, 
another study conducted in Addis Ababa also in Ethiopia found one of the barriers to adherence 
to be pill burden (Gebremariam, Bjune, & Frich, 2010) 
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Participants who agreed that missing doses or taking them incorrectly can ruin their anti-TB 
treatment outcome were about two and half times more likely to default their anti-TB treatment 
in an independent association with a p-value of 0.013 as compared to those who strongly agreed 
to the same. This finding concurs with Adane et al (2013) who found forgetfulness which led to 
missing doses to be associated with high rates of treatment default (Adane et al., 2013). 
Participants who were on anti-TB re-treatment were 3 times more likely to be poorly adherent to 
their anti-TB treatment as compared to those on first time anti-TB treatment in a significant 
independent association with a p-value of 0.049. This is consistent with a study by Peltzer and 
Pengpid (2015) in which patients on anti-TB retreatment were associated with non-adherence to 
anti-TB treatment as compared to those on anti-TB treatment for the first time (Peltzer & 
Pengpid, 2015). 
Surprisingly, our study also found that having electricity in the house hold was also 
independently associated with poor adherence to anti-TB treatment (odds ratio 2.22; p-value 
0.045). This is contrary to a case-control study by Muture et al (2011) who revealed low income 
to be independently associated with default to anti-TB treatment (Muture et al., 2011). Also 
because electricity as a form of energy has been discovered to be a key indicator of the 
standard/quality of living making it also a measure of the income and so economic status of a 
house hold (Joyeux & Ripple, 2004). 
Though participants who did not know that TB can be transmitted through the air appeared to 
have a protective association with adherence to anti-TB treatment (un-adjusted odds ratio 0.26; 
p-value 0.024), no association was retained after confounding was adjusted for (adjusted odds 
ratio 0.35; p-value 0.134). This is commensurate with Peltzer & Pengpid (2015) who revealed 
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association between poor TB knowledge and non-adherence to anti-TB treatment in a bivariate 
analysis (Peltzer & Pengpid, 2015).  
Also, though participants who agreed that benefits of taking anti-TB drugs outweighs any 
difficulties encountered appeared to be protected from poor adherence to anti-TB treatment as 
compared to those who strongly agree with an un-adjusted odds ratios of 0.51 and a p-value of 
0.005, the association was not retained after adjusting for confounding (adjusted odds ratios 0.88; 
p-value 0.757). This reveals to us that any degree of lack of knowledge on TB treatment is 
associated with poor adherence. This is confirmed by a prospective cohort study conducted at 21 
TB treatment centers in India which found that lack of knowledge of importance of regular 
treatment was an absolute risk factor for non-adherence among newly diagnosed pulmonary TB 
patients (Kulkarni et al., 2013). This is further confirmed by Castelnuovo (2010) whose review 
reveled poor knowledge about TB treatment to be associated with defaulting anti-TB treatment 
(Castelnuovo, 2010).   
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CHAPTER SIX: CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS  
From our study on the predictors of poor adherence to anti-TB treatment, we conclude that males 
(>60%) were more affected than females, most of our study participants (71.5%) were 45 years 
and less, 21% did not receive any education, and majority (> 90%) lived alone. We also conclude 
that slightly more than a third (34.5%) of patients on anti-TB treatment in Tororo were poorly 
adherent to anti-TB treatment. We finally conclude that factors found to be independently 
associated with poor adherence to anti-TB treatment include; - a once previous diagnosis of TB, 
perceived anti-TB treatment pill burden, not strongly agreeing that missing doses or taking them 
incorrectly can ruin anti-TB treatment outcome, and surprisingly having electricity in the house 
hold.  
RECOMMENDATIONS 
Patients with history of previous TB diagnosis who are to take adult anti-TB re-treatment should 
be counseled prior and during treatment for better adherence to their anti-TB treatment.  
Patients with perceived pill burden should be counseled to swallow all their medication and to 
should be encouraged by the expected outcome of their anti-TB treatment when they complete it 
as prescribed. This will help abate the chances of quitting medication because of pill burden. 
Fixed dose combinations should be encouraged and DOTS should be encouraged in the 
management of patients in whom pill burden can cause quitting of anti-TB drugs. Also research 
to condense and have the various drugs in one pill should be encouraged to have a long lasting 
solution to this cause of poor adherence.  
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We warranty further research to test and confirm the association between household electricity 
and poor anti-TB treatment adherence. 
In a nutshell, all TB patients should be educated and counseled about anti-TB treatment before 
and during their treatment course with emphasis on relapse or re-infection cases, and we 
warranty a further study to understand the association between household electricity and poor 
adherence to anti-TB treatment.  
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APPENDICES 
APPENDIX 1: Definition of Key Terms 
In the study, the following concepts are conceptually and operationally defined as follows: 
Adherence 
“Adherence to long-term therapy is defined as the extent to which an individual’s behavior 
corresponds to a health care provider’s agreed upon recommendations” (WHO, 2003:3). This 
concurs with the National Institute of Health (2008) where adherence is defined as how closely 
an individual follows a prescribed treatment regimen that includes the willingness to start and the 
ability to take medications as exactly directed. Also, it is defined as behaving according to 
particular rules and or following a set of beliefs (Oxford University Press, 2000:). This further 
concurs with MOH (2008) where it is noted that adherence to TB treatment is when a patient 
takes his/her drugs according to the prescription instructions, following the dosage, number of 
times and number of days without missing any sessions until all the medication is completely 
taken (MOH, 2008). In this study, adherence to anti-TB treatment will be measured as self-
reported by the patient themselves. In our study, patients with history of missing one or more 
prescribed doses will be deemed non-adherent and will be graded by how much they missed their 
medication in the particular period spent on treatment. 
Antiretroviral therapy 
As per WHO (2006), antiretroviral drugs are drugs used to stop the HIV virus multiplication by 
acting through different stages of the HIV life cycle (WHO, 2006:24). Anti-retroviral therapy 
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involves using drug combinations to treat HIV infection where three or more different classes of 
antiretroviral drugs are used in combination. In this study, antiretroviral therapy refers to treating 
HIV using a combination of 3 antiretroviral drugs such as zidovudine, lamivudine and nevirapine 
or efavirenz as first line combination and other combinations such as Truvada plus Alluvia as 
second line combination. 
Compliance 
Compliance is the continuous, correct and uninterrupted taking of prescribed medication as 
directed by the healthcare professional (Aït-Khaled N, Alarcón E, Armengol R, Bissell K, 
Boillot F, Caminero J A, Chiang C-Y, Clevenbergh P, Dlodlo R, Enarson D A, Enarson P, 
Fujiwara P I, Harries A D, Heldal E, Hinderaker S G, Lienhardt C, Monedero I, Rieder H L, 
Rusen I D, Trébucq A, Van Deun, 2010). In this study, compliance will be defined as taking anti-
TB treatment as prescribed at the right time, for the right duration, and at a dosage in line with 
the TB treatment guidelines. Any non-compliance will be defined as not taking anti-TB as 
described above and this includes patients who miss any dose(s) of the TB treatment for 
whatever reason. 
Directly observed therapy shortcourse (DOTS) 
This is an internationally recognized strategy used in the implementation of the basics of TB 
case-finding and cure. It is more than just a clinical approach. It is a strategy for management in 
public health systems and includes, political commitment, case-detection through quality 
bacteriology, short-course chemotherapy while ensuring patient adherence to anti-TB treatment, 
adequate drug supply, and comprehensive recording and reporting systems (WHO, 2006b). 
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Factors 
As defined by the Oxford Advanced Learner's Dictionary (2000), factors are one of the several 
things that cause or influence something or an outcome (Oxford University Press, 2000). In this 
case good or poor/non-adherence to anti-TB treatment. For this study, a factor will be anything 
that affects how patients take or adhere to their anti-TB treatment drugs. 
First-Line TB drugs 
First-Line TB drugs are the drugs used in the treatment of susceptible TB (WHO, 2010:30) and 
for this study they are rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin. 
In line with WHO, these five drugs are recommended by the Uganda National Tuberculosis and 
Leprosy program for treatment of TB most of the time (MOH, 2010:27). 
Incidence 
Incidence is a measure of the probability of occurrence of a given condition in a population 
within a specified period of time. Incidence proportion (cumulative incidence) is the number of 
new cases with a particular condition (which is TB in our study) in a specified period of time per 
population initially at risk (Rothman, Lash, & Greenland, 2008).  
Multidrug-resistant tuberculosis (MDR-TB) 
This is tuberculosis caused by organisms that do not respond to or show resistance to at least two 
of the most powerful first line anti-TB drugs – rifampicin and isoniazid (WHO, 2014a, 2016). In 
this study, MDR-TB meant exactly as defined above. 
Prevalence 
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Prevalence is the number of cases with a particular condition per 10,000 or 100,000 population. 
In this study we used period prevalence which is the number of cases per 100,000 people that 
had Tuberculosis during a one year period, and includes people who already had the condition at 
the start of the study period as well as those who acquired it during that period (Rothman, 
2012:53).  
Rural Uganda 
According to the Oxford Advanced Learner's Dictionary (2000) rural is connected with or like 
the countryside (Oxford University Press, 2000:1035). In this study rural Uganda refers to the 
remote parts of Uganda accessed only through marram roads where most of the local people are 
peasants who depend on subsistence farming with limited or no access to hydroelectric power, 
and limited clean water and health facilities. 
Tuberculosis (TB) 
Tuberculosis is a chronic infectious disease caused by an organism called Mycobacterium 
tuberculosis or Mycobacteria bovis, transmitted through droplet infection when the infected 
person sneezes or coughs, or through drinking of unpasteurized milk from an infected animal; 
presenting with clinical features such as cough, chest pain, sputum production, weight loss, 
fevers and night sweats. It can cause pathology in the lungs, the bones, the kidneys and the spine 
(Aït-Khaled N, Alarcón E, Armengol R, Bissell K, Boillot F, Caminero J A, Chiang C-Y, 
Clevenbergh P, Dlodlo R, Enarson D A, Enarson P, Fujiwara P I, Harries A D, Heldal E, 
Hinderaker S G, Lienhardt C, Monedero I, Rieder H L, Rusen I D, Trébucq A, Van Deun , 
2010:5; MOH, 2012:90-91). For this research, Tuberculosis refers to Tuberculosis that may be 
affecting the lungs, spine, kidneys, bones, and other parts of the body, diagnosed by a medical 
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doctor or physician assistant who will have initiated treatment for the patient. In Tororo, TB is a 
chronic infection caused by bacteria with clinical features that include but not limited to chronic 
cough of two weeks or more, fevers with excessive night sweats, weight loss, and lymph nodes 
enlargement. A TB diagnosis is confirmed by two sputum ZN stain for alcohol acid fast bacilli 
(AAFB) or polymerase chain reaction (PCR) Gene xpert test for HIV positive patients (MOH, 
2012).  
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APPENDIX 2: QUESTIONNAIRE 
Questionnaire in English 
DETERMINANTS OF TB TREATMENT ADHERENCE IN CLIENTS PRESCRIBED ANTI 
TB TREATMENT IN TORORO DISTRICT, UGANDA. SURVEY QUESTIONNAIRE 
Enumerator instructions: Bold Italics 
Name of Health facility (Circle one):  
Tororo Hospital 
Mukujju Health Center 
Nagongera Health center 
STUDY NUMBER:  
(Facility Specific) 
    
To be assigned by Data collector e.g. T001, T002 (T for Tororo hospital), M001 (M for Mukujju 
Health Center), N001 (N for Nagongera Health Center).  
Date   ____ /____ /  2015        (dd/mm/year) 
Result of Interview 
Completed 
Not completed 
 
FINAL STUDY NUMBER:     
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To be assigned by principle researcher.  
  
http://etd.uwc.ac.za/
 100 
 
100 General information (Circle one) 
101 Age of Respondent (Years) < 18  
18-25  
26-35  
36-45  
Above 45  
102 Sex of Respondent Female  
Male  
103 Marital Status. Married 
Single  
Divorced  
Separated  
Cohabiting  
104 Are you the head of the household?  Yes 
No 
105 Have you disclosed your TB status to 
any one? 
Yes  
 No   
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106 To whom have you disclosed your TB 
status?  
Spouse  
Father  
Mother  
Sibling  
Friend  
Other (Specify):  
107 Do you know your HIV status? (If yes 
go to 108, if no go to 111) 
Yes  
No 
108 What is your HIV status? (If positive 
go to 109, if otherwise go to 111) 
Positive  
Negative 
Do not want to disclose  
109 Are you also on ARVs (drugs for 
HIV/AIDS)?  
Yes  
No   
110 Does your spouse know you are HIV 
positive? 
Yes  
No    
111 Are you the Head of your household? Yes 
No 
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112 Are you a permanent or temporary 
resident in the district? 
Permanent  
Temporary 
113 What is your education level?  No education  
Primary  
Secondary 
Post-Secondary 
114 What is your occupational category? Peasant  
Business  
Professional 
Self-employed 
Laborer  
Others (Specify)  
115 What is your average monthly income 
(UGX) 
 
_________________________ 
116 Who do you live with? Alone   
Family 
Friends 
Other (Specify) … …. …. 
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117 How many people live in the house 
including you? 
≤ 3  
4 – 6 
7 – 9 
≥ 10  
118 How many bedrooms are in the house? 
(Circle one) 
            1          2          3        >3  
119 What is your type of water supply?  Piped into the house  
Stand pipe  
Bore hole  
Well/Spring  
Other Specify ….. ….. …..  
120 Is there electricity in your house? Yes 
No 
121 How often do you drink alcohol?  
 
Never  
Rarely/Occasionally  
Weekly, less than 5 drinks  
Daily, less than 3 drinks  
Daily, more than 3 drinks  
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122 How often do you smoke cigarettes? 
 
Never  
Occasionally  
Regularly, less than 5 cigarettes/day  
Regularly, more than 5 cigarettes/day  
123 Do you smoke marijuana?  
 
Never  
Occasionally  
Regularly, less than 5 cigarettes/day  
Regularly, more than 5 cigarettes/day  
124 Do you use crack/cocaine?  
 
Never  
Occasionally  
Regularly, less than 5 times/day  
Regularly, more than 5 times/day  
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200 Access to Information on TB 
201 What is your main source of information on 
anti-TB treatment? (Tick  one response) 
Media  
Health workers  
Relatives  
Friends  
TASO Drama group  
Other (specify)………  
202 What is your preferred choice of 
information transmission? (Tick one 
response)  
 
1. Media 
2. Health workers 
3. Relatives  
4. Friends  
5. TASO Drama group 
6. Other (specify)………. 
203 How else do you access information about 
TB treatment adherence? (Ask respondent to 
indicate preferred source of information) 
1. Media. 
2. Booklets 
3. Relatives 
4. Friends 
5. TASO Drama group 
6. Other (specify)………. 
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204 Have you attended any TB awareness 
campaign in your community? 
1. Yes  
2. No 
205 If Yes, By Who? 1. Ministry of Health 
2. TASO Drama group 
3. NGO 
4. Others Specify……….. 
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300   Adherence 
301 What TB Regimen are you taking currently? 
(Tick One Option.  Request to look at the 
patients’ card if available to get more 
information on this). 
1. 2HERZ/4HR or 2HERZ/6HE  
2. 2HRZ/4HR  
3. 2SHERZ/1HERZ/5HER  
4. Other, Specify ………………….. 
302 How long have you been taking anti-TB 
drugs? (Tick the most approximate) 
1 month  
2 months 
3 months 
4 months 
> 4 months  
303 How many days do you swallow tabs in a 
week? (Indicate the total number)  
 
     ………days a week 
304 How many tablets do you swallow per 
day/week?  
………tabs a day/………tabs a week. 
305 Does anyone monitor or help you with drug 
taking e.g. reminding you to swallow drugs?  
Yes  
No 
306 If yes, who?  Spouse 
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Father  
Mother 
Sibling 
Friend 
Other (Specify): 
307 Except drugs for HIV/AIDS, are you 
currently taking any other drugs for other 
diseases? 
Yes  
No 
308 If yes to the above question, Which other 
disease(s)? 
High blood pressure 
Kidney disease 
Diabetes  
Hepatitis  
Psychiatric condition 
Other Specify …. …. …. 
 Use the phrase in quotes to help respondent get ready for the next set of questions. 
“I would like to ask you about the TB drugs pills that you are taking.  Some people on 
long-term treatment may miss medicines some of the time. It is possible that you may 
have missed a few doses in the past two weeks….” 
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309 What do you think can happen if you miss 
one or more doses of your anti-TB drugs?  
Nothing  
Feel better  
Feel worse  
TB can worsen 
I can get complications  
Pills stop working  
Not sure/I don’t know  
310 What do you think can happen if you miss 
one or more doses of your anti-TB drugs? 
Yes 
No 
311 Have you ever missed pills/doses since you 
commenced this anti-TB treatment? (If  Yes, 
continue with question 310; If No, skip to 
question 400) 
Yes 
No 
312 Please indicate on the line below the point showing your best guess about how much of 
your medication you have taken in the last two weeks (Guide respondent on how to use 
visual analogue scale) 
 
Swallowed    Swallowed   Swallowed 
None/few drugs   averagely    most/all drugs 
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…………………….% 
 For 313 to 316, please tick all that apply.  Basing on the last time you missed your 
pills, can you choose from the reasons below why you probably missed your doses? 
313 Clinical Reasons 
Fear of side effects/toxicity 
Having side effects/toxicity 
Too sick to swallow 
Treatment failure/ordered to stop 
Frequency of dosing inconveniencing  
314 Medication Access 
Ran out of drug supply at home 
Unable to get to facility for drugs (transport) 
Unable to get to facility for drugs (sickness) 
Drug out of stock at hospital/clinic 
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315 Patient Error 
Forgot to take dose 
Felt better and so stopped taking doses 
Shared medications with others 
Lost medications 
Use of traditional medicines instead 
Had travelled and forgot drugs 
316 Situation in the home 
Food security problems 
Family crisis 
Lack of support from family 
Lack of time due to work /other duties 
Depression 
317 Administrative Issues 
Clinic hours of operation not convenient? 
Long queues/waiting time at clinic? 
Lack of confidentiality at clinic?   
Discomfort with clinical staff  
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318 Other patient Concerns  
No privacy to take medication  
Fear of disclosure of TB status 
Poor health care provider attitude 
Interference with daily issues 
 
 
400     Barriers to Adherence 
401 Before this time, how many times have you 
been diagnosed with TB? 
Never  
Once  
Twice 
Thrice or more  
402 Did you complete treatment when you were 
previously diagnosed? 
Yes 
No  
403 If no, why not? (If yes proceed to 404) Pill taking length 
Too many pills 
If I vomit my pills 
If I get anti-TB drugs side effects 
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Fear people finding out my status 
Other, Specify     
404 Do you think you can take pills as prescribed 
for 6 or 8 months? 
Yes  
No 
Don’t know 
405 How far is the hospital from your home (Km) 
(One response required) 
< 2 km  
2 – 4 km  
4 – 6 km  
6 – 8 km  
8 – 10 km 
> 10 km  
406 On average how much time do you take to 
move to and from the hospital to pick your 
anti-TB drugs (minutes.) (One response 
required) 
<30 minutes  
30 – 60 minutes  
60 – 90 minutes  
90 – 120 minutes 
>120 minutes, Specify … … ……. 
……. ……. ……. …….  
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407 Do you have to take time off work to pick up 
your drugs? 
Yes 
No 
408 How do you travel to pick your drugs? Walk 
Bicycle 
Motor cycle 
Car 
Mini-bus 
Other, Specify …………….. 
409 Do you have to pay any transport fare to get 
to the hospital? 
Yes 
No 
410 Have you ever been treated for a Psychiatric 
illness? 
Yes 
No 
411 Have you ever had any difficulties in taking 
your TB drugs regularly? 
Yes 
No 
412 Have you ever had any difficulties in taking 
your TB drugs on time? 
Yes 
No 
413 Have you ever been or felt stigmatized for 
having TB? 
Yes 
No 
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414 Which one of the following could most 
possibly make you want to quit taking your 
TB drugs? (Circle one)  
Pill taking length 
Too many pills 
If I vomit my pills 
If I get anti-TB drugs side effects 
Fear people finding out my status 
Other, Specify    …………………. 
415 Have you experienced any side effects due to 
TB drugs? (If  No, Skip to Question 500)  
Yes 
No 
416 If Yes, Which of the following have you 
experienced? (Circle all that apply) 
Nausea and Vomiting 
Burning in the feet 
Hypersensitive reaction (skin rashes) 
decreased urine output 
Swelling of breasts (males) 
Deafness 
Visual impairment 
Other, specify   …………………… 
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500 Perspective on benefits and/or costs of 
TB treatment (Tick one)  
Strongl
y  
Agree 
Agree  
 
DK Disagree 
 
Strongly 
Disagre
e 
501 The benefits of taking my anti-TB 
drugs outweigh any difficulties I may 
encounter. 
     
502 Taking anti-TB drugs is too 
cumbersome 
     
503 I believe that taking my anti-TB drugs 
is better than not taking them. 
     
504 Taking anti-TB drugs will help me be 
healthy. 
     
505 I don’t think there can be 
improvement in my health if I don’t 
follow my anti-TB treatment plan.  
     
506 TB is life threatening.      
507 TB can worsen HIV/AIDS.       
508 Taking anti-TB drugs poorly can lead 
to complicated TB, drug resistant TB, 
and/or death secondary to TB. 
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DK – Don’t Know.  
 
700 Beliefs and myths about TB. The following statements attempt to capture your 
knowledge and beliefs about TB. For 701, circle the most appropriate response 
701 
 
Through which of the following 
ways do you think you acquired 
TB? 
 
 
1. Being bewitched                   
2. Angering the ancestors         
3. Being cursed     
4. Not sure / Don’t know  
5. Cigarette smoking  
6. Hospital 
7. Through cough of a case 
8. Other (specify)……….                                                                     
 For 702 – 710, tick the most 
appropriate 
Strongly  
Agree 
Agree  
 
DK Disagree 
 
Strongly 
Disagree 
702 Traditional healers can help heal 
TB. 
     
703 Even if I don’t complete my anti-TB 
treatment, TB can completely cure.  
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704 TB can be transmitted through the 
air? 
     
705 Living in congested houses with 
poor circulation increases chances 
of transmitting/contracting TB? 
     
706 Taking and completing my anti-TB 
treatment as prescribed is vital for 
my healing from TB?   
     
707 After the first two weeks of 
regularly swallowing my anti-TB 
drugs, the chances of transmitting 
TB to my family decreases.  
     
708 I have to swallow anti-TB drugs for 
6 or 8 months. 
     
709 The time at which the medication is 
taken will influence its effectiveness 
     
710 Missing doses, taking them late/ 
incorrectly can ruin my treatment 
outcome 
     
DK – Don’t Know.  
Thank you for your time and patience. 
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Questionnaire in Swahili 
VIGEZO YA KIFUA KIKUU MATIBABU UZINGATIAJI KATI YA WAGONJWA JUU YA 
KUPAMBANA NA KIFUA KIKUU MATIBABU KATIKA TORORO, UGANDA 
DODOSA YA UTAFITI 
Maelekezo ya Enumerator Italiki ni ujasiri: 
Jina la hospitali (Jibu majibu moja):  
Tororo Hospital 
Mukujju Health Center 
Nagongera Health center 
STUDY NUMBER:  
(Kutoka hospitali ya mgojwa) 
    
Kuwekewa Data collector e.g. T001, T002 (T ya Tororo hospital), M001 (M ya Mukujju Health 
Center), N001 (N ya Nagongera Health Center).  
Tarehe   ____ /____ /  2015        (siku/mwezi/mwaka) 
Kutokana ya Mahojiano  
1. Kukamilika 
2. Si kukamilika  
 
FINAL STUDY NUMBER:     
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Kupewa principle researcher. 
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100 Mkuu wa habari (Uwanja moja) 
101 Umri wa Mhojiwa (Miaka) < 18  
18-25 
26-35 
36-45 
Zaidi ya 45 
102 Jinsia (Ngono) ya kujibu 
 
kike 
Kiume 
103 Hali ya ndoa Ndoa 
Si ndoa 
Talaka 
Kinachotenganishwa 
Kinyumba na  
104 Je, wewe ni mkuu wa kaya?  Ndiyo 
Hapana 
105 Je, ilisema hali yako kifua kikuu kwa 
mtu yeyote? 
Ndiyo 
Hapana 
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106 Ambaye je wazi hali yako kifua 
kikuu? 
Mke 
Bwana 
Baba 
Mama 
Ndugu/dada 
Rafiki  
Nyingine (Taja): 
107 Je, unajua hali yako ya VVU? (Kama 
ndiyo kwenda 108, kama hakuna 
kwenda kwa 111) 
Ndiyo  
Hapana 
108 Hali yako ya VVU ni nini? (Kama 
chanya kwenda 109, ikiwa 
vinginevyo kwenda 111) 
Chanya 
Si chanya 
Je, si unataka kufichua  
109 Je, pia kumeza dawa kwa ajili ya 
VVU UKIMWI? 
Ndiyo 
Hapana   
110 Je, mke wako anajua una VVU? Ndiyo 
Hapana 
111 Je, wewe ni Mkuu wa kaya yako? Ndiyo 
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Hapana 
112 Je, wewe ni kudumu mkazi au ya 
muda mkazi katika wilaya? 
Kudumu mkazi  
 Muda mkazi  
113 Masomo yako iliofika wapi?   Sija soma 
Msingi 
Sekondari 
Nili pitia-Sekondari 
114 Una fanya kazi gani? Wakulima 
Biashara 
Mtaalamu 
Kujiajiri 
Mfanyakazi 
Wengine (Taja) 
115 Kila Mwezi, unapata pessa ngapi? 
(Shillingi ya Uganda) 
 
_________________________ 
116 Na ninyi je kuishi na? Peke yangu 
Familia 
Na wa rafiki 
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Wangine (Taja) … …. …. 
117 Watu wangapi wanaishi katika 
nyumba ikiwa ni pamoja na wewe?  
≤ 3 
4 – 6 
7 – 9 
≥ 10  
118 Jinsi vyumba wengi katika nyumba? 
(Chaguwa au mduara moja) 
            1          2          3        > 3  
119 Ni aina yako ya ugavi wa maji ni 
nini? 
 
Bomba ndani ya nyumba 
Bomba  ingye 
Bore shimo 
Naam / spring 
Nyingine (Taja).. ... .. ... .. 
120 Je, kuna umeme katika nyumba 
yako? 
Ndiyo 
Hapana 
121 Ni mara ngapi wewe kunywa pombe? 
 
Kamwe 
Mara chache / mara kwa mara 
Kila wiki, chini ya vinywaji 3 
Kila siku, chini ya vinywaji 3 
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Kila siku, zaidi ya vinywaji 3 
122 Ni mara ngapi wewe moshi sigara? 
 
Kamwe 
Mara kwa mara 
Mara kwa mara, chini ya sigara 5 / siku 
4. Mara kwa mara, zaidi ya sigara 5 / siku 
123 Je, moshi bangi? 
 
Kamwe 
Mara kwa mara 
Mara kwa mara, chini ya bangi 5 / siku 
Mara kwa mara, zaidi ya bangi 5 / siku 
124 Je, matumizi ya ufa / cocaine?  
 
Kamwe 
Mara kwa mara 
Mara kwa mara, chini ya mara 5 / siku 
Mara kwa mara, zaidi ya mara 5 / siku 
 
200 Kupata habari juu ya kifua kikuu 
201 Chanzo yako kuu wa habari juu ya 
matibabu ya kupambana na kifua 
kikuu ni nini? (Jibu majibu moja) 
Vyombo vya Habari 
Afya wafanyakazi 
Jamaa 
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Marafiki 
Kundi ya TASO ya mchezo wa kuigiza 
6. Nyingine (Taja)......... 
202 Uchaguzi wako preferred ya 
maambukizi habari ni nini? (Jibu 
majibu moja) 
 
Vyombo vya Habari 
Afya wafanyakazi 
Jamaa 
Marafiki 
Kundi ya TASO ya mchezo wa kuigiza 
Nyingine (Taja)......... 
203 Jinsi ywingine gani unaweza kupata 
habari kuhusu uzingatiaji matibabu 
kifua kikuu? (Waulize kujibu 
zinaonyesha preferred chanzo cha 
habari) 
 
1. Vyombo vya habari. 
2. Vijitabu 
3. Jamaa 
4. Marafiki 
5. Kundi ya TASO ya mchezo wa kuigiza 
6. nyingine (Taja).......... 
204 Je, kuhudhuria kifua kikuu yoyote 
kampeni ya ufahamu katika jamii 
yako? 
1. Ndiyo 
2. Hakuna 
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205 Kama ndiyo, na nani?  1. Wizara ya Afya 
2. Kundi ya TASO ya mchezo wa kuigiza 
3. Shirika ya siyo ya kiserikari  
4. Wengine (Taja) ......... .. 
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300   Kuzingatia 
301 Nini kifua kikuu Regimen ni wewe 
kuchukua kwa sasa? (Jibu Moja chaguo. 
Ombi kuangalia kadi wagonjwa 'kama ipo 
kupata habari zaidi juu ya hili). 
1. 2HERZ/4HR or 2HERZ/6HE 
2. 2HRZ/4HR 
3. 2SHERZ/1HERZ/5HER 
4. Nyingine, (Taja) ..................... .. 
302 Kwa muda gani umekuwa kutumia dawa 
kifua kikuu? (Jibu takriban zaidi) 
 
1. Miezi 2 
2. Miezi 3 
3. Miezi 4 
4. Kupita Miezi 4 
303 Siku ngapi unameza tabo katika wiki? 
(Zinaonyesha jumla ya idadi) 
      
 
 
   Siku ......... kwa wiki moja 
304 Jinsi tabo (vidonge) ngapi unameza kwa 
siku au kwa wiki?  
 
Tabo ......... kwa siku / Tabo ......... kwa 
wiki  
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305 Je, mtu yeyote kufuatilia au kukusaidia na 
kumeza dawa, mfano kuku kumbusha 
kumeza dawa yako?  
Ndiyo  
Hapana 
306 Kama ndiyo, nani? 1. Mke 
2. Baba 
3. Mama 
4. Sibling 
5. Rafiki 
6. Nyingine (Taja) ………… 
307 Ukiwache dawa za VVU UKIMWI, je sasa 
una chukua dawa nyingine yoyote kwa ajili 
ya magonjwa mengine? 
Ndiyo 
Hapana 
308 Kama ndiyo kwa swali hapo juu, ugonjwa 
mwingine yupi? 
 
Shinikizo la damu 
Ugonjwa wa Figo 
Kisukari 
Ugonjwa wa Maini 
Ugonjwa wa kuzungumika kichwa 
Nyingine (Taja) .... .... 
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 Kutumia maneno katika kunukuu kusaidia kujibu kupata tayari kwa ajili ya kuweka pili 
ya maswali.  "Napenda kukuuliza kuhusu dawa za TB dawa kuwa wewe ni kuchukua. 
Baadhi ya watu juu ya matibabu ya muda mrefu inaweza miss madawa baadhi ya 
wakati. Inawezekana kwamba unaweza kuwa amekosa dozi chache katika wiki mbili 
zilizopita .... " 
309 Unafikiri yanaweza kutokea kama miss dozi 
moja au zaidi ya madawa ya kulevya yako 
ya kupambana na kifua kikuu? 
 
1. Hakuna 
2. Kujisikia Vizuri 
3. Sikiya Vibaya 
4. Kifua Kikuu Inaweza Kuwa Mbaya 
5. Naweza Kupata matatizo 
6. Vidonge kuacha kufanya kazi 
7. Uhakika / Sijui  
310 Je, amekosa dawa yoyote / dozi katika 
kipindi cha wiki 2 zilizopita? 
Ndiyo  
Hapana 
311 Umewahi amekosa dawa / dozi tangu 
kuanza matibabu hayo kupambana na kifua 
kikuu? (Kama Ndiyo, kuendelea na swali 
312, Kama ni hapana, ruka swali 400) 
Ndiyo  
Hapana 
312  
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Tafadhali eleza kwenye mstari chini ya kiwango kuonyesha nadhani wako bora kwa 
kiasi gani dawa zako wamechukua katika kipindi cha wiki mbili zilizopita (Uongoza 
mujibu juu ya jinsi ya kutumia wadogo Visual analog) 
Kukata tamaa                                    na kukata tamaa                                         
Nimemeza  
Hakuna / madawa chache                    huvyo hivyo                                    zaidi / dawa 
zote 
 
 
                                        
…………………….%  
 Kwa 313-316, tafadhali Jibu zote zinazotumika. Kutgemeana na mara ya mwisho 
j’olimekosa dawa yako, unaweza kuchagua sababu chini kwa nini pengine amekosa 
dozi yako? 
313 Hospitali Sababu 
Hofu ya madhara / simu 
Kuwa na madhara /simu 
Wugonjwa sana kumeza 
Matibabu kushindwa / kuamuru kuacha 
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Mzunguko ya dozi 
314 Dawa Kupata 
Mbio nje ya usambazaji wa madawa ya kulevya nyumbani 
Haiwezekani kupata kituo kwa ajili ya madawa ya kulevya (usafiri) 
Haiwezekani kupata kituo kwa ajili ya madawa ya kulevya (ugonjwa) 
Dawa nje ya hisa katika hospitali / kliniki 
315 Mgonjwa Kosa 
Umesahau kuchukua dozi 
Nilisikia bora na VVU yo kusimamishwa kuchukua dozi 
Pamoja dawa na wengine 
Waliopotea dawa 
Matumizi ya dawa za asili badala 
Alisafiri na kusahau madawa 
316 Hali katika nyumba 
Matatizo Usalama wa chakula 
Familia mgogoro 
Kukosekana kwa msaada kutoka kwa familia 
Ukosefu wa muda kutokana na kazi / majukumu mengine 
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Unyogovu 
317 Tawala Masuala 
Kliniki masaa ya kazi si rahisi? 
Muda foleni / kusubiri muda katika kliniki? 
Ukosefu wa usiri katika kliniki? 
Usumbufu na wafanyakazi kliniki  
318 Wasiwasi nyingine mgonjwa 
Hakuna faragha kuchukua dawa 
Hofu ya kutoa taarifa ya hali ya kifua kikuu 
Huduma Afya duni mtoa tabia 
Kuingilia masuala ya kila siku 
 
 
400     Vikwazo vya Kuzingatia 
401 Kabla ya wakati huu, ni mara ngapi 
umekuwa kukutwa na kifua kikuu? 
 
1. Kamwe 
2. Mara 
3. Mara mbili kwa 
4. Mara tatu au zaidi  
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402 Je, matibabu kamili wakati wewe hapo awali 
kukutwa?  
Ndiyo  
Hapana  
403 Kama hapana, kwa nini? (Kama ndiyo 
kuendelea na 404) 
 
1. Kidonge kuchukua urefu 
2. Dawa Wengi mno 
3. Kama mimi matapishi dawa yangu 
4. Kama mimi kupata kupambana na 
kifua kikuu na madhara ya madawa ya 
kulevya 
5. Hofu watu kutafuta hali yangu 
6. Nyingine, (Taja)… …. ….  
404 Je, unafikiri unaweza kuchukua dawa kama 
ilivyoagizwa kwa ajili ya 6 au 8 miezi? 
1. Ndiyo 
2. Hapana 
3. Sijui 
405 Jinsi mbali ni hospitali kutoka nyumbani 
kwako (Km) (majibu moja inahitaji) 
< 2 Km 
2 – 4 Km 
4 – 6 Km 
6 – 8 Km 
8 – 10 Km 
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> 10 Km 
406 Kwa wastani ni kiasi gani wakati gani 
kuchukua kwa hoja na kutoka hospitali ili 
kubaini kupambana na kifua kikuu yako ya 
kulevya (dakiika) (majibu moja inahitaji) 
dakiika < 30  
dakiika 30 – 60 
dakiika  60 – 90  
dakiika  90 – 120  
dakiika  >120 (Taja) …… ……  
407 Je, una kuchukua muda mbali na kazi 
kuchukua dawa yako? 
Ndiyo  
Hapana 
408 Jinsi gani unaweza kusafiri ili kubaini dawa 
yako? 
 
1. Kutembea 
2. Baiskeli 
3. Pikipiki 
4. Gari 
5. Mini-bus  
6. Nyingine, (Taja) ...............  
409 Je, una kulipa nauli yoyote usafiri wa kupata 
hospitali? 
Ndiyo  
Hapana 
410 Umewahi kutibiwa kwa ugonjwa wa akili Ndiyo  
Hapana 
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411 Umewahi matatizo yoyote katika kutumia 
dawa yako kifua kikuu mara kwa mara? 
 
Ndiyo  
Hapana 
412 Umewahi matatizo yoyote katika kutumia 
dawa yako kifua kikuu kwa wakati?  
 
Ndiyo  
Hapana 
413 Je, umewahi kuwa au waliona unyanyapaa 
kwa kuwa na kifua kikuu? 
Ndiyo  
Hapana 
414 yupi moja ya yafuatayo inaweza zaidi 
uwezekano wa kufanya unataka kuacha 
kutumia dawa yako kifua kikuu? (Uwanja 
moja)  
1. Kidonge kuchukua urefu 
2. Dawa Wengi mno 
3. Kama mimi matapishi dawa yangu 
4. Kama mimi kupata kupambana na 
kifua kikuu na madhara ya madawa ya 
kulevya 
5. Hofu watu kutafuta hali yangu 
6. Nyingine, (Taja) ...................... 
415 Je, uzoefu madhara yoyote kutokana na 
madawa ya kulevya kifua kikuu? (Kama ni 
hapana, Ruka kwa swali 500) 
Ndiyo  
Hapana 
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416 Kama Ndiyo, yupi kati ya zifuatazo na wewe 
na uzoefu? (Uwanja zote zinazotumika) 
 
1. Kichefuchefu na kutapika 
2. Kusikia Motto katika miguu 
3. Vipele kwenye ngozi 
4. Ilipungua pato mkojo 
5. Kuvimba ya matiti (wanaume) 
6. Uziwi 
7. Kuharibika 
8. Nyingine, (Taja)........................ 
 
500 Mtazamo juu ya faida na / au 
gharama za matibabu kifua kikuu 
(jibu moja) 
K
u
b
al
i 
sa
n
a 
K
u
b
al
ia
n
a 
S
ij
u
i 
H
aw
ak
u
b
al
ia
n
i 
H
aw
ak
u
b
al
ia
n
i 
sa
n
a 
 
501 Faida za kutumia dawa zangu za  
kupambana na kifua kikuu zina 
shinda matatizo yoyote ninaweza 
kukutana. 
     
502 Kuchukua madawa ya TB ni mbaya 
mno 
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503 Naamini kuwa kutumia dawa za 
kupambana na kifua kikuu yangu ni 
bora kuliko kutopata yao. 
     
504 Kuchukua madawa ya TB itanisaidia 
kuwa na afya. 
     
505 Sidhani kuna kuwa uboreshaji katika 
afya yangu kama mimi hawafuati 
matibabu mpango wangu kupambana 
na kifua kikuu. 
     
506 Kifua kikuu ni kutishia maisha      
507 Kifua kikuu inaweza kuwa mbaya 
VVU / UKIMWI. 
     
508 Kuchukua madawa ya kifua kikuu 
vibaya inaweza kusababisha ngumu 
kifua kikuu, na kifua kikuu sugu, na / 
au kifo sekondari kwa kifua kikuu. 
     
 
700 Imani na imani potofu kuhusu kifua kikuu. Kauli ifuatayo kujaribu kukamata maarifa 
na imani yako kuhusu kifua kikuu. Kwa 701, mduara majibu sahihi zaidi 
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701 
 
Njia ambayo ya njia zifuatazo 
unafikiri alipewa kifua kikuu? 
 
 
 
1. Kuwa rogwa 
2. Kuwaudha Mababu 
3. Kuwa walaani 
4. Si uhakika / Sijui 
5. Kuvuta sigara 
6. Hospitali 
7. Kupitia kikohozi ya kesi 
8. Nyingine (Taja) ..........                              
 
Kwa 702-710, Jibu sahihi zaidi 
K
u
b
al
i 
sa
n
a 
K
u
b
al
ia
n
a 
S
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u
i 
H
aw
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u
b
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n
i 
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u
b
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n
i 
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n
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702 Waganga wa jadi wanaweza 
kusaidia kuponya TB. 
     
703 Hata kama mimi si kukamilisha 
matibabu yangu kupambana na 
kifua kikuu, kifua kikuu wanaweza 
kabisa tiba. 
     
704 kifua kikuu huweza kuambukizwa 
kwa hewa? 
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705 Wanaoishi katika nyumba 
msongamano na ongezeko maskini 
mzunguko nafasi ya kupeleka / 
kuambukizwa kifua kikuu? 
     
706 Kumeza na kukamilisha matibabu 
yangu kupambana na kifua kikuu 
kama ilivyoagizwa ni muhimu kwa 
ajili ya uponyaji wangu kutoka kifua 
kikuu? 
     
707 Baada ya wiki mbili za kwanza 
mara kwa mara kumeza dawa yangu 
kupambana na kifua kikuu, nafasi ya 
kupeleka kifua kikuu kwa familia 
yangu itapungua. 
     
708 Nina kumeza madawa ya kifua 
kikuu kwa ajili ya 6 au 8 miezi. 
     
709 Wakati ambapo dawa ni 
kuchukuliwa kuwa na mvuto ufanisi 
wake 
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710 Kukosa dozi, kuwapeleka 
marehemu / kimakosa unaweza 
uharibifu matibabu yangu matokeo 
 
     
 
 
Asante kwa muda wako na uvumilivu 
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APPENDIX 3: PARTICIPANT INFORMATION SHEET 
INFORMATION SHEET  
 
Project Title: Determinants of TB Treatment Adherence among patients prescribed anti-TB 
treatment in Tororo Hospital, Uganda  
What is this study about?  
This is a research project being conducted by Barasa Alex Wanyama at the University of the 
Western Cape.  We are inviting you to participate in this research project because you are a 
patient prescribed anti TB drugs in Tororo hospital, you have been on these drugs for at least a 
month, and this study is to describe poor adherence and factors that influence adherence among 
persons on anti-TB treatment in Tororo hospital. This study purpose is to give us the actual 
picture of the factors associated with poor adherence to TB treatment among persons prescribed 
anti-TB treatment in Tororo hospital Uganda. This will consequently be used to improve the 
management of Tuberculosis through addressing the determinants of poor adherence to TB 
treatment.  
What will I be asked to do if I agree to participate? 
You will be asked to participate in the above research where you will be asked questions by an 
interviewer who will ask you questions while and recording your responses into the 
questionnaire. The study will be conducted in Tororo hospital, and it will take an average of 
about 20 – 30 minutes for the interviewer guided questionnaire to be completed. The questions to 
be asked will be structured and closed ended with options for you to choose. The questionnaire 
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will include questions such as your age, sex, religion, marital status, education level, financial 
status, anti-TB treatment history, anti-TB treatment adherence status, distance from health 
facility, and presence of co-infections. 
Would my participation in this study be kept confidential? 
We will do our best to keep your personal information confidential.  To help protect your 
confidentiality, we shall assign a number instead of your name, your name will not appear on any 
data collection instrument, the data collected will be kept in a confidential place under lock and 
key and will require a secret code in order to be accessed on the computer. Through the use of an 
identification key, the researcher will be able to link your survey to your identity; and only the 
researcher will have access to the identification key. If we write a report or article about this 
research project, your identity will not be revealed. 
What are the risks of this research? 
There may be some risks from participating in this research study. These include staying longer 
as you are being interviewed, or getting your service a little late because of your participation in 
the study after having the questionnaire completed.   
What are the benefits of this research? 
This research is not designed to help you personally, but the results may help the investigator 
learn more about determinants of anti-TB treatment adherence. We hope that in the future, other 
people will benefit from this study through better understanding and improved policies of anti-
TB treatment especially as regards to adherence to treatment, and the best way to implement 
these policies to achieve best results for people on anti-TB treatment.  
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Do I have to be in this research and may I stop participating at any time?   
Your participation in this research is completely voluntary.  You may choose not to take part at 
all.  If you decide to participate in this research, you may stop participating at any time.  If you 
decide not to participate in this study or if you stop participating at any time, you will not be 
penalized or lose any benefits to which you otherwise qualify.  
Is any assistance available if I am negatively affected by participating in this study? 
Any assistance that you may need if negatively affected by the research study procedures will be 
accorded you such as counselling and referral for care and any other.  
What if I have questions? 
This research is being conducted by Barasa Alex Wanyama at the University of the Western 
Cape.  If you have any questions about the research study itself, please contact Barasa Alex 
Wanyama at: P. O. Box 34104 Kampala Uganda, Tel +256 79 176 2709, and E-mail 
alexb2ug@gmail.com. Should you have any questions regarding this study and your rights as a 
research participant or if you wish to report any problems you have experienced related to the 
study, please contact:   
 
Director: 
Prof Helene Schneider 
School of Public Health 
University of the Western Cape 
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Private Bag X17 
Bellville 7535         
hschneider@uwc.ac.za  
 
Dean of the Faculty of Community and Health Sciences:  
Prof Jose Frantz 
University of the Western Cape 
Private Bag X17 
Bellville 7535         
chs-deansoffice@uwc.ac.za  
 
This research has been approved by the University of the Western Cape’s Senate Research 
Committee and Ethics Committee.  
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APPENDIX 4: CONSENT FORM 
CONSENT FORM 
Title of Research Project:  
 
Determinants of TB Treatment Adherence among patients on anti-TB treatment in Tororo 
district, Uganda 
 
The study has been described to me in language that I understand and I freely and voluntarily agree 
to participate.  
My questions about the study have been answered. I understand that my identity will not be 
disclosed and that I may withdraw from the study without giving a reason at any time and this will 
not negatively affect me in any way.   
 
Participant’s name : ……………………………… 
Participant’s signature : ……………………………….      
Date : ……………………… 
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APPENDIX 5: TERMS OF REFERENCE FOR DATA COLLECTORS AND 
COORDINATOR 
Determinants of TB Treatment Adherence in Clients Prescribed Anti-TB Treatment in 
Tororo District, Uganda. 
Data collection 
 
Terms of reference for Data collectors (Interviewers)  
1. Recruit and introduce the study participants to the study and provide an information sheet 
to the study participant 
2. Facilitate and acquire signed informed consent from the study participants 
3. Assign facility specific study number (criteria is explained in the questionnaire) 
4. Guide and assist the respondent through the questionnaire as an interviewer 
5. Ensure accurate and complete data is collected 
6. Proof read questionnaire for completeness 
7. Keep completed questionnaires safe from anyone else awaiting handing them to the 
coordinator 
8. Adhere to ethics during the whole data collection exercise 
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Determinants of TB Treatment Adherence in Clients Prescribed Anti-TB Treatment in 
Tororo District, Uganda. 
Data collection 
 
Terms of reference for Coordinator 
1. Recruit and introduce the study participants to the study and provide an information sheet 
to the study participant 
2. Facilitate and acquire signed informed consent from the study participants 
3. Assign facility specific study number (criteria is explained in the questionnaire) 
4. Guide and assist the respondent through the interviewer guided questionnaire  
5. Receive all the answered questionnaires 
6. Proof read all answered questionnaires for completeness 
7. Assign the final study number 
8. Keep all the questionnaires in a safe place (lockable cabin) to ensure confidentiality 
9. Coordinate the data collection process between the 3 health facilities 
10. Ensure accuracy and timelines of data 
11. Pay remuneration/compensation to the data collectors 
12. Enter data into excel spreadsheet 
13. Contact principle researcher in case of any queries  
14. Adhere to ethics during the whole data collection exercise 
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APPENDIX 6: UWC RESEARCH PROJECT REGISTRATION AND ETHICS 
CLEARANCE APPLICATION 
                                                                                                                                               SR1         
UWC RESEARCH PROJECT REGISTRATION AND ETHICS CLEARANCE 
APPLICATION FORM 
 
This application will be considered by UWC Faculty Board and Research Committees, then by the 
UWC Senate Research Committee [SR]. SR may also consult outsiders on ethics questions, or 
consult the UWC ethics subcommittees, before registration of the project and clearance of the 
ethics.  No project should proceed before project registration and ethical clearance has been 
granted. 
 
A.     PARTICULARS OF INDIVIDUAL APPLICANT 
 
NAME: Barasa Alex Wanyama                                     TITLE: Doctor 
 
 
 
UNIVERSITY of the WESTERN CAPE 
DEPARTMENT OF RESEARCH DEVELOPMENT 
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DEPARTMENT:                                                         FACULTY: Community and Health Sciences 
 
FIELD OF STUDY: Public Health 
ARE YOU: 
A member of UWC academic staff? 
A member of UWC support staff? 
A registered UWC student? 
From outside UWC, wishing to research at or with UWC? 
 
Yes  
Yes 
Yes 
Yes 
 
 
 
 
 
 
No 
No 
No 
No 
 
  
 
 
 
 
B. PARTICULARS OF PROJECT 
PROJECT NUMBER:  TO BE ALLOCATED BY SENATE RESEARCH COMMITTEE:  
EXPECTED COMPLETION DATE: 
PROJECT TITLE:  
Determinants of TB Treatment Adherence among patients on anti TB Treatment in Tororo district, 
Uganda 
THREE KEY WORDS DESCRIBING PROJECT: 
Tuberculosis (TB), anti-TB treatment, determinants of TB treatment adherence 
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PURPOSE OF THE PROJECT: 
M-DEGREE: MPH (Mini Thesis)                                                          D-DEGREE: 
POST GRADUATE RESEARCH: 
C.     PARTICULARS REGARDING PARTICULAR RESEARCHERS 
                                                                       FAMILY NAME:         INITIALS:                         TITLE: 
PRINCIPAL RESEARCHER:          Barasa      A W                        Doctor 
OTHER RESEARCH PROJECT LEADERS: 
 
 
OTHER CO-RESEARCHERS: 
 
 
THESIS:  STUDENT RESEARCHER: Barasa Alex Wanyama 
THESIS: SUPERVISOR: Ms Verona Mathews 
 
 
D. GENERAL INFORMATION 
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STUDY LEAVE TO BE TAKEN DURING PROECT (days): 
 
IS IT INTENDED THAT THE OUTCOME WILL BE SUBMITTED FOR PEER REVIEWED 
PUBLICATION? 
YES        NO      
 
COMMENTS:           DEPARTMENTAL CHAIRPERSON: 
 
SIGNATURE OF THESIS STUDENT RESEARCHER – WHERE APPROPRIATE: 
                                                      DATE: April 30, 2015 
SIGNATURE OF THESIS SUPERVISOR – WHERE APPROPRIATE: 
                                                                            DATE 
SIGNATURE OF PRINCIPAL RESEARCHER – WHERE APROPRIATE: 
                                                                            DATE: 
SIGNATURE OF DEPARTMENTAL CHAIRPERSON: 
                                                                            DATE: 
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NOTE:  THESE SIGNATURES IMPLY AN UNDERTAKING BY THE RESEARCHERS, TO 
CONDUCT THE RESEARCH ETHICALLY, AND AN UNDERTAKING BY THE THESIS 
SUPERVISOR (WHERE APPROPRIATE), AND THE DEPARTMENTAL CHAIRPERSON, TO 
MAINTAIN A RESPONSIBLE OVERSIGHT OVER THE ETHICAL CONDUCT OF THE 
RESEARCH. 
 
 
E.     DESCRIPTION OF PROJECT AND RESEARCH ETHICS STATEMENT 
Abstract 
Poor adherence to treatment remains a barrier to management and control of many infections including 
Tuberculosis (TB). Adherence to TB treatment is the strongest determinant of tuberculosis treatment 
outcome, and can result into treatment failure, multi-drug resistant TB (MDR-TB), or death if not 
addressed. Poor adherence to TB therapy is one of the major obstacles in the global fight against TB, 
and there is need to identify treatment default predictive factors. Uganda is one of the high TB burden 
countries in Africa with an incidence of 166 per 100,000 population, a prevalence of 0.154% and a 
mortality of 11 per 100,000 population (WHO, 2015). Prevention and control of TB is one of the 
priority services of the Ugandan health sector. In Tororo hospital, no study of poor adherence to anti-
TB treatment has been done before and the level and factors that lead to poor adherence in patients on 
anti-TB treatment in Tororo hospital are not known.  
Aim: Our study aim is to investigate adherence levels and explore factors that influence adherence 
among persons on anti TB Treatment in Tororo district. 
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Study Design: Cross-sectional Study Design.  
Study Population: All TB patients on anti TB Treatment for at least 2 months in Tororo hospital.  
Data Collection: Two trained research assistants will be employed to collect data through 
administering questionnaires. Participants will be recruited and interviewed on drugs refill days.  
Analysis: The data collected from the questionnaire will be captured into Epi info software and 
analyzed for descriptive statistics such as frequency distributions, and measures of central tendency 
and dispersion. Inferential analysis will be conducted using logistic regression for both bivariate and 
univariate analysis using a 5% level of significance. 
ETHICS CONSIDERATIONS  
An application for ethics approval to undertake the study will be submitted to the UWC Ethics 
committee. Permission to collect data from patients in Tororo hospital will be requested from Tororo 
Hospital authorities. Participation will be voluntary without any form of coercion. Information sheets 
explaining the study details, benefits, the study’s voluntary nature, and assurance of confidentiality 
and privacy will be availed to the participants in both English and Swahili and will be explained further 
by the research assistants. Informed consent will be sought and only signed by patients who accept to 
participate in the study. Privacy will be enhanced by administering the questionnaire to one patient at 
a time in the absence of other patients. The identities of all participants will be kept secret by using 
codes instead of participants' names, and all collected information will be stored privately in a lockable 
cabinet. Participants who may develop psychological or emotional harm will be referred to the health 
counsellor for help.   
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APPENDIX 7: LETTERS OF APPROVAL TO CONDUCT THE STUDY 
Letter of approval from University of Western Cape Ethics committee 
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Letter of approval from Tororo District Local Government Health Office 
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